WO2003024402A2 - Lpa receptor agonists and antagonists and methods of use - Google Patents
Lpa receptor agonists and antagonists and methods of use Download PDFInfo
- Publication number
- WO2003024402A2 WO2003024402A2 PCT/US2002/029593 US0229593W WO03024402A2 WO 2003024402 A2 WO2003024402 A2 WO 2003024402A2 US 0229593 W US0229593 W US 0229593W WO 03024402 A2 WO03024402 A2 WO 03024402A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chain
- alkyl
- branched
- edg
- lpa
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title claims abstract description 133
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims abstract description 69
- 239000000018 receptor agonist Substances 0.000 title claims description 15
- 229940044601 receptor agonist Drugs 0.000 title claims description 15
- 239000002464 receptor antagonist Substances 0.000 title description 15
- 229940044551 receptor antagonist Drugs 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 230000000694 effects Effects 0.000 claims abstract description 104
- 239000000556 agonist Substances 0.000 claims abstract description 45
- 210000000056 organ Anatomy 0.000 claims abstract description 43
- 230000006907 apoptotic process Effects 0.000 claims abstract description 28
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 279
- 239000000203 mixture Substances 0.000 claims description 114
- 125000000217 alkyl group Chemical group 0.000 claims description 94
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 claims description 48
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 210000001519 tissue Anatomy 0.000 claims description 38
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 19
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 claims description 17
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 claims 5
- 102100030160 Protein BUD31 homolog Human genes 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 31
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 201000011510 cancer Diseases 0.000 abstract description 25
- 239000005557 antagonist Substances 0.000 abstract description 24
- 230000004663 cell proliferation Effects 0.000 abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 231
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 207
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 107
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 106
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 91
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 84
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 67
- 230000004044 response Effects 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 63
- 239000000243 solution Substances 0.000 description 62
- MBDSUZSCJLRKPC-QGZVFWFLSA-N 1,2-dioctanoyl-sn-glycerol 3-diphosphate Chemical compound CCCCCCCC(=O)OC[C@H](COP(O)(=O)OP(O)(O)=O)OC(=O)CCCCCCC MBDSUZSCJLRKPC-QGZVFWFLSA-N 0.000 description 60
- 210000000287 oocyte Anatomy 0.000 description 60
- 239000011541 reaction mixture Substances 0.000 description 58
- 230000002829 reductive effect Effects 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 53
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 53
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 49
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 48
- 108020003175 receptors Proteins 0.000 description 48
- -1 alkenyl glycerol phosphate Chemical compound 0.000 description 46
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 42
- 239000000543 intermediate Substances 0.000 description 41
- 238000001819 mass spectrum Methods 0.000 description 41
- 238000011282 treatment Methods 0.000 description 40
- 150000002632 lipids Chemical class 0.000 description 38
- 229910019142 PO4 Inorganic materials 0.000 description 37
- 238000007792 addition Methods 0.000 description 37
- 235000021317 phosphate Nutrition 0.000 description 36
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 35
- 241000269370 Xenopus <genus> Species 0.000 description 34
- 239000012300 argon atmosphere Substances 0.000 description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 238000003818 flash chromatography Methods 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 24
- 239000010452 phosphate Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 230000035755 proliferation Effects 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000009471 action Effects 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 206010033128 Ovarian cancer Diseases 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- 238000005984 hydrogenation reaction Methods 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 18
- 230000029663 wound healing Effects 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 239000012298 atmosphere Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 17
- 229940067631 phospholipid Drugs 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 16
- 238000012512 characterization method Methods 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 16
- 238000010791 quenching Methods 0.000 description 16
- 101000871096 Homo sapiens Probable G-protein coupled receptor 45 Proteins 0.000 description 15
- 206010060862 Prostate cancer Diseases 0.000 description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 229910052763 palladium Inorganic materials 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 102100033048 Probable G-protein coupled receptor 45 Human genes 0.000 description 14
- 101000736116 Xenopus laevis High-affinity lysophosphatidic acid receptor Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 13
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 13
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 13
- 150000001982 diacylglycerols Chemical class 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 150000008103 phosphatidic acids Chemical class 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 102000036530 EDG receptors Human genes 0.000 description 12
- 108091007263 EDG receptors Proteins 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000004679 31P NMR spectroscopy Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000005340 bisphosphate group Chemical group 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- HDFFVHSMHLDSLO-UHFFFAOYSA-M dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)([O-])OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-M 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000009087 cell motility Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000002241 neurite Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 229940045860 white wax Drugs 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108091006027 G proteins Proteins 0.000 description 8
- 102000030782 GTP binding Human genes 0.000 description 8
- 108091000058 GTP-Binding Proteins 0.000 description 8
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 101150062285 PGF gene Proteins 0.000 description 8
- 108010081690 Pertussis Toxin Proteins 0.000 description 8
- 102100035194 Placenta growth factor Human genes 0.000 description 8
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 235000011180 diphosphates Nutrition 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 230000002297 mitogenic effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 150000003141 primary amines Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 7
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000012292 cell migration Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000010531 catalytic reduction reaction Methods 0.000 description 6
- 230000004709 cell invasion Effects 0.000 description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 6
- 230000010005 growth-factor like effect Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- HRJDEHQWXAPGBG-YFKPBYRVSA-N tert-butyl n-[(3s)-2-oxooxetan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1COC1=O HRJDEHQWXAPGBG-YFKPBYRVSA-N 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- IWYRWIUNAVNFPE-UHFFFAOYSA-N Glycidaldehyde Chemical compound O=CC1CO1 IWYRWIUNAVNFPE-UHFFFAOYSA-N 0.000 description 5
- 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 5
- VOEQFNGSVZKIOT-UHFFFAOYSA-N LysoPA(8:0/0:0) Chemical compound CCCCCCCC(=O)OCC(O)COP(O)(O)=O VOEQFNGSVZKIOT-UHFFFAOYSA-N 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 102000003923 Protein Kinase C Human genes 0.000 description 5
- 108090000315 Protein Kinase C Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 5
- 241000269368 Xenopus laevis Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 229940095074 cyclic amp Drugs 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 125000005313 fatty acid group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 238000005556 structure-activity relationship Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 125000005490 tosylate group Chemical group 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- 150000000185 1,3-diols Chemical class 0.000 description 4
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- BFVRFWIQTACAPT-KRWDZBQOSA-N N-Palmitoyl serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(O)=O BFVRFWIQTACAPT-KRWDZBQOSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 210000003567 ascitic fluid Anatomy 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 4
- 230000003534 oscillatory effect Effects 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 150000003408 sphingolipids Chemical class 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 3
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102000011420 Phospholipase D Human genes 0.000 description 3
- 108090000553 Phospholipase D Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 102000004446 Serum Response Factor Human genes 0.000 description 3
- 108010042291 Serum Response Factor Proteins 0.000 description 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 108010049273 Xenopus PSP24 receptor Proteins 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000001621 anti-mitogenic effect Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 125000003180 beta-lactone group Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 3
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012577 media supplement Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102000000568 rho-Associated Kinases Human genes 0.000 description 3
- 108010041788 rho-Associated Kinases Proteins 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- JLVSPVFPBBFMBE-HXSWCURESA-N sphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000003518 stress fiber Anatomy 0.000 description 3
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
- 229960005314 suramin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- HSMUPNYJCMYKJH-KRWDZBQOSA-N (2s)-2-(hexadecanoylamino)-3-phosphonooxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)COP(O)(O)=O HSMUPNYJCMYKJH-KRWDZBQOSA-N 0.000 description 2
- MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical class OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N 2,3-dihydroxypropyl heptadecanoate Chemical compound CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- QSKPZDMBULYMDQ-UHFFFAOYSA-N 2,3-dihydroxypropyl pentadecanoate Chemical compound CCCCCCCCCCCCCCC(=O)OCC(O)CO QSKPZDMBULYMDQ-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 2
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000212384 Bifora Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 0 CCCN*(C)C*=C Chemical compound CCCN*(C)C*=C 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 2
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 2
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 2
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 2
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001274216 Naso Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical class OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 2
- 102000042463 Rho family Human genes 0.000 description 2
- 108091078243 Rho family Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 2
- BMTUFQKYWWLCLC-UHFFFAOYSA-K [hydroxy(oxido)phosphoryl] phosphate;tetrabutylazanium Chemical compound OP([O-])(=O)OP([O-])([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC BMTUFQKYWWLCLC-UHFFFAOYSA-K 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 210000001650 focal adhesion Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000052301 human GNAZ Human genes 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- ILCRQWHDNXNAMG-UHFFFAOYSA-N nonadecane-9,10,11-triol phosphono dihydrogen phosphate Chemical compound OP(O)(=O)OP(=O)(O)O.C(CCCCCCC)C(C(C(O)CCCCCCCC)O)O ILCRQWHDNXNAMG-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- WRKCIHRWQZQBOL-UHFFFAOYSA-N phosphoric Acid Monooctyl Ester Natural products CCCCCCCCOP(O)(O)=O WRKCIHRWQZQBOL-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- DTXNTEFOJDJREL-BQAIUKQQSA-N (2s)-2-(hexadecanoylamino)-3-(4-hydroxyphenyl)propanoic acid;phosphoric acid Chemical class OP(O)(O)=O.CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DTXNTEFOJDJREL-BQAIUKQQSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- SFPCGPWJDDRSRL-UHFFFAOYSA-N 1-(4,5-dihydroimidazol-1-yl)ethanone Chemical compound CC(=O)N1CCN=C1 SFPCGPWJDDRSRL-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-HSZRJFAPSA-N 1-hexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-N 0.000 description 1
- UMEKPPOFCOUEDT-UHFFFAOYSA-N 1-icosanoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO UMEKPPOFCOUEDT-UHFFFAOYSA-N 0.000 description 1
- LAYXSTYJRSVXIH-HXUWFJFHSA-N 1-stearoyl-sn-glycero-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O LAYXSTYJRSVXIH-HXUWFJFHSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 1
- WWTTXMMZHOBTAM-UHFFFAOYSA-N 2,3-dihydroxypropyl nonadecanoate Chemical compound CCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO WWTTXMMZHOBTAM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- QTWGZFFHIUZYBK-UHFFFAOYSA-N 2-amino-3-hydroxy-n-nonylpropanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCCCCCCNC(=O)C(N)CO QTWGZFFHIUZYBK-UHFFFAOYSA-N 0.000 description 1
- QQUPMFSWVHAPED-UHFFFAOYSA-N 2-amino-3-hydroxy-n-octadecylpropanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCCCCCCCCCCCCCCCNC(=O)C(N)CO QQUPMFSWVHAPED-UHFFFAOYSA-N 0.000 description 1
- WQAIJIICCXNRDK-UHFFFAOYSA-N 2-amino-3-hydroxy-n-tetradecylpropanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCCCCCCCCCCCNC(=O)C(N)CO WQAIJIICCXNRDK-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- IXZBAJOADDIGIP-UHFFFAOYSA-N 2-tetradecoxyaniline Chemical compound CCCCCCCCCCCCCCOC1=CC=CC=C1N IXZBAJOADDIGIP-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- VNDKIXPLPLIGJV-UHFFFAOYSA-N 3-tetradecoxyaniline Chemical compound CCCCCCCCCCCCCCOC1=CC=CC(N)=C1 VNDKIXPLPLIGJV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- SGHYUZKXTRJREF-UHFFFAOYSA-N 4-tetradecoxyaniline Chemical compound CCCCCCCCCCCCCCOC1=CC=C(N)C=C1 SGHYUZKXTRJREF-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000934426 Homo sapiens Cell division control protein 42 homolog Proteins 0.000 description 1
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 description 1
- 101001122162 Homo sapiens Overexpressed in colon carcinoma 1 protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000007757 Media 199 Substances 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 102100027063 Overexpressed in colon carcinoma 1 protein Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224486 Physarum polycephalum Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical group C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- VVAKEYFJZPPFTI-UHFFFAOYSA-N [2-amino-3-(4-methoxyanilino)-3-oxopropyl] dihydrogen phosphate Chemical compound COC1=CC=C(NC(=O)C(N)COP(O)(O)=O)C=C1 VVAKEYFJZPPFTI-UHFFFAOYSA-N 0.000 description 1
- BUBQGYVAPQROMH-UHFFFAOYSA-N [2-amino-3-(nonylamino)-3-oxopropyl] dihydrogen phosphate Chemical compound CCCCCCCCCNC(=O)C(N)COP(O)(O)=O BUBQGYVAPQROMH-UHFFFAOYSA-N 0.000 description 1
- ONJBMTZEYAIDNR-UHFFFAOYSA-N [2-azaniumyl-3-(octadecylamino)-3-oxopropyl] hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCNC(=O)C(N)COP(O)(O)=O ONJBMTZEYAIDNR-UHFFFAOYSA-N 0.000 description 1
- MBCYDVXEMDWKEJ-UHFFFAOYSA-N [2-azaniumyl-3-oxo-3-(tetradecylamino)propyl] hydrogen phosphate Chemical compound CCCCCCCCCCCCCCNC(=O)C(N)COP(O)(O)=O MBCYDVXEMDWKEJ-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 102000000072 beta-Arrestins Human genes 0.000 description 1
- 108010080367 beta-Arrestins Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- BNMJSBUIDQYHIN-UHFFFAOYSA-N butyl dihydrogen phosphate Chemical compound CCCCOP(O)(O)=O BNMJSBUIDQYHIN-UHFFFAOYSA-N 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002783 cell motility assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VQNFXZODDQLONE-UHFFFAOYSA-N dibenzyl butyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCCCC)OCC1=CC=CC=C1 VQNFXZODDQLONE-UHFFFAOYSA-N 0.000 description 1
- SKBUSMXPQCOAJV-UHFFFAOYSA-N dibenzyl docosyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCCCCCCCCCCCCCCCCCCCCCC)OCC1=CC=CC=C1 SKBUSMXPQCOAJV-UHFFFAOYSA-N 0.000 description 1
- QZGRXVPTCFCWQD-UHFFFAOYSA-N dibenzyl dodecyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCCCCCCCCCCCC)OCC1=CC=CC=C1 QZGRXVPTCFCWQD-UHFFFAOYSA-N 0.000 description 1
- VTNBMGVEAPMXOM-UHFFFAOYSA-N dibenzyl octadecyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCCCCCCCCCCCCCCCCCC)OCC1=CC=CC=C1 VTNBMGVEAPMXOM-UHFFFAOYSA-N 0.000 description 1
- CHCAFOAHDDBACE-UHFFFAOYSA-N dibenzyl octyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCCCCCCCC)OCC1=CC=CC=C1 CHCAFOAHDDBACE-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LNTZHXQMPUKVNX-UHFFFAOYSA-N docosyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOP(O)(O)=O LNTZHXQMPUKVNX-UHFFFAOYSA-N 0.000 description 1
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000008317 extracellular mechanism Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108700025906 fos Genes Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045812 human GPR45 Human genes 0.000 description 1
- 102000045903 human LPA Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- HQNWZXVJHYLMAU-UHFFFAOYSA-N n-[bis[(2-methylpropan-2-yl)oxy]phosphoryl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(=O)(OC(C)(C)C)OC(C)(C)C HQNWZXVJHYLMAU-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- UHGIMQLJWRAPLT-UHFFFAOYSA-N octadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP(O)(O)=O UHGIMQLJWRAPLT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000001006 phagokinetic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000030503 positive regulation of chemotaxis Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- YHEDRJPUIRMZMP-ZWKOTPCHSA-N sphinganine 1-phosphate Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)COP(O)(O)=O YHEDRJPUIRMZMP-ZWKOTPCHSA-N 0.000 description 1
- 125000002657 sphingoid group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/17—Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/4028—Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
Definitions
- This invention relates to lysophosphatidic acid (“LPA”) derivatives which have activity as either agonists or antagonists on LPA receptors and various therapeutic uses thereof including, but not limited to, prostate cancer therapy, ovarian cancer therapy, and wound healing.
- LPA lysophosphatidic acid
- PLGFs phospholipid growth factors
- PLGFs can be sub-divided structurally into two broad categories.
- the first category contains the glycerophospholipid mediators (GPMs), which possess a glycerol backbone.
- GPMs include LPA, phosphatidic acid (PA), cyclic phosphatidic acid (cyclic-PA), alkenyl glycerol phosphate (alkenyl-GP), and lysophosphatidyl serine (LPS).
- the second category contains the sphingolipid mediators (SPMs), which possess a sphingoid base motif.
- Exemplary SPMs include sphingosine-1 -phosphate (SPP), dihydrosphingosine-1- phosphate, sphingosylphosphorylcholine (SPC), and sphingosine (SPH).
- LPA is a key intermediate in the early stages of phospholipid biosynthesis, which takes place predominantly in the membrane of endoplasmic reticulum (ER) (Bosch, 1974; Bishop and Bell, 1988).
- ER endoplasmic reticulum
- LPA is derived from the action of Acyl-CoA on glycerol-3-phosphate, which is further acylated to yield PA. Because the rate of acylation of LPA to PA is very high, very little LPA accumulates at the site of biosynthesis (Bosch, 1974). Since LPA is restricted to the ER, its role as a metabolic intermediate is most probably unrelated to its role as a signaling molecule.
- LPA is a constituent of serum and its levels are in the low micromolar ( ⁇ M) range (Eicholtz et al., 1993). This level is expected because LPA is released by activated platelets during the coagulation process. Unlike serum, it is not detectable in fresh blood or plasma (Tigyi and Miledi, 1992; Eicholtz et al., 1993). LPA that is present in the serum is bound to albumin, and is responsible for a majority of the heat- stable, and non-dialysable biological activity of the whole serum (Moolenaar, 1994).
- the active serum component that is responsible for eliciting an inward chloride current inXenopus oocyte was indentified to be LPA (18:0) (Tigyi and Miledi, 1992).
- LPA The active serum component that is responsible for eliciting an inward chloride current inXenopus oocyte was indentified to be LPA (18:0) (Tigyi and Miledi, 1992).
- the bulk of the albumin-bound LPA(18:0) is produced during the coagulation process, rather than by the action of lysophospholipase D (PLD) on lyso-PC.
- PLD lysophospholipase D
- the latter pathway is responsible for the presence of LPA in 'aged' plasma that has been de- coagulated by the action of heparin or citrate plus dextrose (Tokumura et al., 1986).
- Another point to note is that LPA is not present in plasma that has been treated with ED
- albumin The role of albumin is to protect LPA from the actions of phospholipases present in the serum (Tigyi and Miledi, 1992). Tigyi and Miledi suggested that albumin not only acts as a carrier of LPA in the blood stream, but also increases its physiological half-life. There are yet unidentified lipid mediators present in serum albumin that mimic the actions of LPA in eliciting chloride current in
- LPA-responsive cell types extend from slime mold amoebae and Xenopus oocyte to mammalian somatic cells. Thus, it seems likely that the source of LPA and its release may not be restricted only to activated platelets. Recent experiments showed that, on stimulation by peptide growth factors, mammalian fibroblasts rapidly produce LPA, which is followed by its release into the extracellular medium (Fukami and Takenawa, 1992).
- GPMs and SPMs elicit a wide variety of cellular responses that span the phylogenetic tree (Jalink et al., 1993a).
- LPA induces transient Ca 2+ signals that originate from intracellular stores in a variety of cells such as neuronal (Jalink et al.,
- LPA when added to quiescent fibroblasts, stimulates DNA synthesis and cell division (van Corven et al., 1989; van Corven et al., 1992).
- the growth-like effects of LPA do not require the presence of peptide growth factors. This observation makes LPA different from endothelin or vasopressin, which require the presence of insulin or epidermal growth factor (Moolenaar, 1991) to sustain cell proliferation.
- endothelin or vasopressin which require the presence of insulin or epidermal growth factor (Moolenaar, 1991) to sustain cell proliferation.
- a point to note is that, in Sp 2 myleoma cells, LPA was responsible for an antimitogenic response, which was mediated by an increase in cAMP levels (Tigyi et al., 1994;
- LPA also promotes the reversal and suppression of neuroblastoma differentiation by inducing the retraction of developing neurites (Jalink et al., 1994a ; Jalink et al., 1994b).
- LPA When a continuous presence of LPA is provided, neuroblastoma cells maintain their undifferentiated phenotype, but fail to undergo mitosis (Jalink et al., 1993b).
- LPA-induced neurite retractions result from the contraction of the actin-cytoskeleton, rather than from loss of adhesion to the substratum (Jalink et al.,
- LPA similar to other physiological chemoattractants (e.g., interleukin- 8), induces cell migration by a haptotactic mechanism in human monocytes (Zhou et al., 1995). In addition to inducing cell migration, LPA promotes the invasion of hepatoma and carcinoma cells into the monolayer of mesothelial cells (Imamura et al.,
- LPA is also known to block neonatal cardiomyocyte apoptosis (Umansky et al., 1997).
- cyclic-PA A unique natural phospholipid, namely cyclic-PA, was shown to be responsible for cellular actions that were similar to or opposite to other GPMs, depending on the cell type.
- cyclic-PA When tested on the Xenopus oocyte, it elicited chloride current just like other GPMs; but its response was not desensitized by LPA (Fischer et al., 1998).
- Murakami-Murofushi et al. (1993) showed that cyclic-PA exhibited antiproliferative actions, unlike LPA, which induces proliferation.
- PLGF receptors belong to a seven-transmembrane (7 TM) guanine nucleotide-binding regulatory protein (G protein)-coupled receptors (GPCR) superfamily. Seven-TM GPCRs are a family of cell-surface receptors that mediate their cellular responses via interacting with the heterotrimeric G-protein. A number of LPA receptors have been identified including, among others, EDG-2, EDG-4, EDG-7, and PSP-24. A phylogenetic tree illustrating the relatedness of these LPA receptors and others is shown in Figure 1.
- Vzg-1 ventricular zone gene-1
- EDG-2 endothelial differentiation gene-2
- EDG-2 As a functional receptor for LPA prompted An et al. to perform a sequence-based search for a novel subtype of LPA receptor (An et al., 1998a).
- Northern blot analysis showed that, although
- EDG-2 and EDG-4 both serve as GPM receptors, their tissue distributions were very different. Unlike EDG-2, EDG-4 was primarily expressed in peripheral blood leukocytes and testes (An et al., 1998a).
- PCR amplification cDNA from human Jurkat T cells identified a previously unknown GPCR that belongs to the EDG family.
- the identified GPCR was designated EDG-7. It has a molecular mass of 40 kDa (353 amino acids).
- Northern blot analysis of EDG-7 expression in human tissues showed that it is expressed in heart, pancreas, prostate, and testes (Bandoh et al., 1999).
- PSP24 and EDG there are two distinct families of PLGFs receptors PSP24 and EDG; with a total often individual PLGFRs ( Figure 1). The list continues to grow.
- Xenopus PSP24 and murine expressed PSP24 specifically transduce GPM (LPA, Fischer et al., 1998) evoked oscillatory chloride-currents. These are not structurally homologous to the EDG family (Tigyi and Miledi, 1992; Fernhout et al., 1992).
- the EDG family can be divided into two distinct subgroups. The first group includes EDG-2, EDG-4, and EDG-7, which serve as receptors for only GPM (Hecht et al., 1996; An et al., 1998a; Bandoh et al., 1999; An et al., 1998b) and transmit numerous signals in response to ligand binding.
- the second group involves EDG-1, EDG-3, EDG-5, EDG-6, and EDG-8, and is specific for SPMs (An et al., 1997a; Im et al., 2000; van Brocklyn et al., 1998; van Brocklyn et al., 2000; Spiegel and Milstein, 2000).
- SPMs SPMs
- PLGFs activate multiple G-protein-mediated signal transduction events. These processes are mediated through the heterotrimeric G-protein families G q/ ⁇ , G / o, and G 12/ ⁇ 3 (Moolenaar, 1997; Spiegel and Milstein, 1995; Gohla, et al., 1998).
- the G q/ ⁇ pathway is responsible for phospholipase C (PLC) activation, which in turn induces inositol triphosphate (IP 3 ) production with subsequent mobilization of Ca 2+ in a wide variety of cells (Tokumura, 1995). In some cells, this response is PTX-sensitive, implying that there is involvement of multiple PTX- sensitive and insensitive pathways (Tigyi et al., 1996). This pathway is also responsible for the diacyl glycerol (DAG)-mediated activation of protein kinase C (PKC).
- DAG diacyl glycerol
- PKC activates cellular phospholipase D (PLD), which is responsible for the hydrolysis of phosphatidyl choline into free choline and PA (van der Bend et al., 1992a). Also, PLC is capable of activating MAP kinase directly, or via DAG activation of PKC in some cell types (Ghosh et al., 1997).
- the mitogenic-signaling pathway is mediated through the G-protein heterotrimeric G, /0 subunit.
- Transfection studies indicate that the Gj ⁇ dimer rather than the ⁇ i subunit is responsible for Ras-MAP kinase activation.
- the activation of Ras is preceded by the transactivation of the receptor tyrosine kinases (RTKs) such as EGF (Cunnick et al., 1998) or PDGF receptors (Herrlich et al., 1998).
- the transactivated RTKS activate Ras, which leads to the activation of MAP kinases (ERK 1,2) via Raf.
- the phosphorylated receptor is recruited by ⁇ -arrestin, thus recruiting src kinase, which phosphorylates the EGF-receptor, generating its active conformation (Lin et al., 1997; Ahn et al., 1999; Luttrell et al., 1999).
- the transactivated RTKs in turn, activate Ras, which leads to the activation of MAP kinases (ERK 1,2) via Raf.
- cyclic- AMP cyclic- AMP
- LPA cyclic- AMP
- mitogenesis is mediated through the G, ⁇ pathway, which results in decreased levels of c AMP (van Corven et al., 1989; van Corven et al., 1992), whereas antimitogenesis is accompanied by a non-
- Rho a small GTPase
- MLC-phosphatase myosin light chain phosphatase
- Rho The PLGF-induced, Rho- mediated, tumor cell invasiveness is blocked by C. Botulinium C3-toxin, which specifically ribosylates Rho in an ADP-dependent mechanism (Imamura et al., 1996). Rho also has the ability to stimulate DNA synthesis in quiescent fibroblasts (Machesky and Hall, 1996; Ridley, 1996). The expression of Rho family
- GTPase activates serum-response factor (SRF), which mediates early gene transcription (Hill et al., 1995).
- SRF serum-response factor
- LPA PLGF
- LPA/LPA receptor involvement in a number of cellular pathways and cell activities such as proliferation and/or migration, as well as their implication in wound healing and cancer, it would be desirable to identify novel compounds which are capable of acting, preferably selectively, as either antagonists or agonists at the LPA receptors identified above.
- SPP inhibits tumor cell invasiveness, but it is uncertain whether SPP does so by being an inhibitor of LPA or via the actions of its own receptors.
- N-palmitoyl-1-serine and N-palmitoyl-1-tyrosine also inhibited LPA- induced platelet aggregation (Sugiura et al., 1994), but it remains to be seen whether these compounds act at the LPA receptor.
- Lysophosphatidyl glycerol (LPG) was the first lipid to show some degree of inhibition of LPA actions (van der Bend et al., 1992b), but it was not detectable in several LPA-responsive cells types (Liliom et al.,
- a polysulfonated compound, Suramin was shown to inhibit LPA- induced DNA synthesis in a reversible and dose-dependent manner. However, it was shown that Suramin does not have any specificity towards the LPA receptor and blocked the actions of LPA only at very high millimolar (mM) concentrations (van Corven et al., 1992).
- the present invention is directed to overcoming the deficiencies associated with current LPA agonists and LPA antagonists.
- the present invention relates to compounds according to formula (I) as follows:
- X 3 are linked together as — N(H)— C(O)— N(R ! )— ; optionally, one of X 1 , X 2 , and X 3 is H; A is either a direct link, (CH 2 ) ⁇ with k being an integer from 0 to 30, or O;
- Y 1 is — (CH 2 ) — with / being an integer from 1 to 30, — O — , O
- Z 1 is — (CH 2 ) m — or — O(CH 2 ) m — with m being an integer from 1 to 50, — C(R 3 )H— , — NH— — O— , or — S— ;
- Z 2 is — (CH 2 ) protest — or — O(CH 2 ) admir — with n being an integer from 1 to 50 or — O— ;
- R 1 for each of X 1 , X 2 , or X 3 , is independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri- substitutions of the ring, an acyl including a CI to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, an aryloxyalkyl including straight or branched-chain CI to C30 alkyl,
- R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri- substitutions of the ring, an acyl including a CI to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, or an aryloxyalkyl including straight or branched-chain CI to C30 alkyl; wherein the compound of formula I is not lysophosphatidic acid, phosphatidic acid, cyclic phosphatidic acid, alkenyl glycerolphosphate, dioctyl glycerol pyrophosphate, or N-palmitoyl-L-serine.
- compositions which include a pharmaceutically-acceptable carrier and a compound of the present invention.
- a further aspect of the present invention relates to a method of inhibiting LPA activity on an LPA receptor which includes providing a compound of the present invention which has activity as an LPA receptor antagonist and contacting an LPA receptor with the compound under conditions effective to inhibit LPA-induced activity of the LPA receptor.
- Another aspect of the present invention relates to a method of modulating LPA receptor activity which includes providing a compound of the present invention which has activity as either an LPA receptor agonist or an LPA receptor antagonist and contacting an LPA receptor with the compound under conditions effective to modulate the activity of the LPA receptor.
- Still another aspect of the present invention relates to a method of treating cancer which includes providing a compound of the present invention and administering an effective amount of the compound to a patient in a manner effective to treat cancer.
- Yet another aspect of the present invention relates to a method of enhancing cell proliferation which includes providing a compound the present invention which has activity as an agonist of an LPA receptor and contacting the LPA receptor on a cell with the compound in a manner effective to enhance LPA receptor- induced proliferation of the cell.
- a further aspect of the present invention relates to a method of treating a wound which includes providing a compound of the present invention which has activity as an agonist of an LPA receptor and delivering an effective amount of the compound to a wound site, where the compound binds to LPA receptors on cells that promote healing of the wound, thereby stimulating LPA receptor agonist-induced cell proliferation to promote wound healing.
- a still further aspect of the present invention relates to a method of making the compounds of the present invention.
- One approach for making the compounds of the present invention includes: reacting (Y 2 O) 2 PO— Z 11 — Z 13 or (Y 2 O) 2 PO— Z 12 — P(OH)O— Z 11 — Z 13 , where
- Z 1 ' is — (CH ) m — or — O(CH 2 ) m — with m being an integer from 1 to 50, — C(R 3 )H— , or — O— ;
- Z 12 is — (CH 2 ) folk — or — O(CH 2 ) admir — with n being an integer
- Z 13 is H or a first leaving group or — Z 1 ' — Z 13 together form the first leaving group
- Y 2 is H or a protecting group, with an intermediate compound according to formula (NI)
- NI where, at least one ofX u , X 12 , and X 13 is R 11 — Y n — A— with each being the same or different when two of X 11 , X 12 , and X 13 are R 11 — Y 1 '—A— , or X 12 and X 13 are linked together as — ⁇ (H)— C(O)—
- N(R ⁇ at least one of X 11 , X 12 , and X 13 is OH, NH 2 , SH, or a second leaving group; optionally, one of X 11 , X 12 , and X 13 is H;
- A is either a direct link, (CH ) with k being an integer from 0 to 30, or O;
- Y u is — (CH 2 ) / — with / being an integer from 1 to 30, — O — , O
- R 11 for each of X 11 , X 12 , or X 13 , is independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without
- C30 alkyl or an aromatic or heteroaromatic ring an arylalkyl including straight or branched-chain CI to C30 alkyl, an aryloxyalkyl including straight or branched-chain CI to C30 alkyl,
- R 12 , R 13 , R 14 , R 15 , R 16 , and R are independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain
- Yet another aspect of the present invention relates to a method of treating apoptosis or preserving or restoring function in a cell, tissue, or organ which includes: providing a compound of the present invention which has activity as an agonist of an LPA receptor; and contacting a cell, tissue, or organ with an amount of the compound which is effective to treat apoptosis or preserve or restore function in the cell, tissue, or organ.
- a further aspect of the present invention relates to a method of culturing cells which includes: culturing cells in a culture medium which includes a compound of the present invention which has activity as an agonist of an LPA receptor and is present in an amount which is effective to prevent apoptosis or preserve the cells in culture.
- Another aspect of the present invention relates to a method of preserving an organ or tissue which includes: providing a compound of the present invention which has activity as an agonist of an LPA receptor; and treating an organ or tissue with a solution comprising the compound in an amount which is effective to preserve the organ or tissue function.
- a related aspect of the present invention relates to an alternative method of preserving an organ or tissue which includes: providing a compound of the present invention which has activity as an agonist of an LPA receptor; and administering to a recipient of a transplanted organ or tissue an amount of the compound which is effective to preserve the organ or tissue function
- a still further aspect of the present invention relates to a method of treating a dermatological condition which includes: providing a compound of the present invention which has activity as an LPA receptor agonist; and topically administering a composition comprising the compound to a patient, the compound being present in an amount which is effective to treat the dermatological condition
- the compounds of the present invention which have been identified herein as being either agonists or antagonists of one or more LPA receptors find uses to inhibit or enhance, respectively, biochemical pathways mediated by LPA receptor signaling. By modulating LPA receptor signaling, the antagonists and agonists find specific and substantial uses in treating cancer and enhancing wound healing.
- Figure 1 is a phylogenetic tree illustrating the classification and relatedness often phospholipid growth factor receptors, including LPA receptors EDG-2, EDG-4, EDG-7, and PSP-24 ( ⁇ , ⁇ ).
- Figure 2 illustrates the synthesis scheme employed for preparation of serine amide compounds 35-43.
- Figure 3 illustrates the synthesis scheme employed for preparation of serine amide phosphate compounds 55-59.
- Figure 4 illustrates the synthesis scheme employed for preparation of biphosphate compounds 66-68.
- Figures 5A-B illustrate synthesis of biphosphate compounds.
- Figure 5 A illustrates the synthesis scheme employed for preparation of 1 ,2-biphosphate compounds 85-92.
- Figure 5B illustrates a synthesis scheme for preparing 1,3- biphosphate compounds.
- FIGS. 6A-B illustrate synthesis schemes for preparation of pyrophosphate compounds.
- Figures 7A-C illustrate synthesis schemes for preparation of substituted mono-phosphates and mono-phosphonates from a tosylate-protected di-ether intermediate.
- Figure 8 illustrates the synthesis scheme employed for preparation of straight-chain fatty acid phosphate compounds 106-110.
- Figure 9 illustrates synthesis of straight-chain thiophosphoric acid monoalkyl esters.
- Figure 10 illustrates synthesis of straight-chain alkylamido-phosphoric acid.
- Figure 11 illustrates a synthesis scheme for preparation of conformationally restrained, cyclic phosphate compounds.
- Figure 12 illustrates a synthesis scheme for preparation of conformationally restrained, cyclic phosphate compounds.
- Figure 13 illustrates a synthesis scheme for preparation of conformationally restrained, cyclic phosphate compounds.
- Figure 14 illustrates a synthesis scheme for preparation of conformationally restrained compounds with a free phosphate moiety.
- Figure 15 illustrates an alternative synthesis scheme for preparing 2- monophosphates.
- Figure 16 illustrates an alternative synthesis scheme for preparing 1,3- bisphosphate compounds.
- Figure 17 illustrates a synthesis scheme for preparing compounds having an — N(H) — acyl group as X 3 .
- Figure 18 illustrates a synthesis scheme for preparing compounds having an — N(H) — imidazole group as X 3 .
- Figure 19 illustrates a synthesis scheme for preparing compounds having an — N(H)— C(O)— O— R 7 as X 3 .
- Figure 20 illustrates a synthesis scheme for preparing compounds having an — N(H)— C(S)— O— R 7 as X 3 .
- Figure 21 is a graph illustrating the dose-dependent inhibition of LPA- induced chloride cu ⁇ ents in Xenopus oocytes by extracellular application of 56 (SAP, 14:0).
- Figure 22 is a graph illustrating the dose-dependent inhibition of LPA- induced chloride cu ⁇ ents in Xenopus oocytes by extracellular application of 57 (SAP, 18:0).
- FIGS 23 A-B are graphs illustrating the dose-dependent inhibition of LPA-induced chloride currents in Xenopus oocytes by extracellular application of 66 (MAGDP, 18:0). The a ⁇ ow indicates the time of the intracellular injection of 5 ⁇ M 66, followed by the extracellular application of LPA.
- Figure 24 is a graph illustrating dose-inhibitory effect of 66 (MAGDP,
- Figure 25 is a graph illustrating the dose-dependent inhibition of LPA- induced chloride currents in Xenopus oocytes by extracellular application of 92
- Figure 26 is a graph illustrating the dose-dependent effect of 56a (SDAP, 14:0/2:0) on Xenopus oocytes.
- Figure 27 is a bar graph depicting the effects of compounds 56 (SAP, 14:0), 56a (SDAP, 14:0/2:0), and 66 (MAGDP, 18:0) on LPA-induced HEY cell migration.
- Test compound concentration was 1 ⁇ M; LPA concentration was 0.1 ⁇ M.
- Figures 28A-C are graphs illustrating the dose response relationship for Ca 2+ responses in RH7777 cells heterologously expressing Edg-2 (28A), Edg -4 (28B), or Edg -7 (28C). Each data point represents the average of at least three measurements ⁇ S.D.
- Figures 29A-D are graphs illustrating DGPP 8:0 inhibition of Ca 2+ responses elicited by LPA in Edg-2 and -7, but not Edg-4 expressing RH7777 cells.
- RH7777 cells, expressing Edg-2, -4, or -7, were exposed to a mixture of 100 nM LPA 18:1 and 1 ⁇ M DGPP 8:0.
- Control cells were exposed to 100 nM LPA 18:1.
- Representative Ca 2+ responses are shown for stable Edg-2 (29 A), Edg-4 (29B), and
- FIGS. 30A-C are graphs which illustrate the pharmacological characterization of the inhibition of the LPA response by DGPP 8:0 in RH7777 cells expressing Edg-7 (Edg-7 cells).
- Cells were exposed to a 250 nM concentration of LPA 18:1 mixed with increasing concentrations of DGPP 8:0 and the peak area of the resulting Ca 2+ responses were measured (30A).
- Cells were also exposed to increasing concentrations of LPA 18:1 mixed with a 500 nM concentration of DGPP 8:0 (30B).
- Edg-7 cells were exposed to a 250 nM concentration of LPA 18:1 mixed with a 500 nM concentration of the indicated lipid (30C).
- the peak areas of the Ca 2+ responses are represented as the average values of a minimum of three measurements ⁇ S.D.
- Figures 31 A-C are graphs which illustrate the pharmacological characterization of the inhibition of the LPA response by DGPP 8:0 in RH7777 cells expressing Edg-2 (Edg-2 cells).
- Stable Edg-2 cells exposed to a 250 nM concentration of LPA 18:1 mixed with increasing concentrations of DGPP 8:0 and peak areas of the Ca 2+ responses were measured (31 A).
- Edg-2 cells were exposed to increasing concentrations of LPA 18:1 mixed with a 10 ⁇ M concentration of DGPP 8:0 (31B).
- Edg-2 cells exposed to a 250 nM concentration of LPA 18:1 mixed with a 10 ⁇ M concentration of the indicated lipid (31C). Responses are represented as the average values of a minimum of three measurements ⁇ S.D.
- Figures 32A-B are graphs which illustrate the structure-activity relationship for DGPP in Edg-4-expressing RH7777 cells.
- Stable Edg-4 cells were exposed to a 500 nM concentration of LPA 18:1 mixed with a 5 ⁇ M concentration of the indicated lipids (32A).
- Cells transiently expressing Edg-4 cells were exposed to a 100 nM concentration of LPA 18:1 mixed with a 1 ⁇ M concentration of the indicated lipids (32B).
- the peak areas of the Ca 2+ responses were measured and are represented as the average values of a minimum of three measurements ⁇ S.D.
- Figures 33 A-C are graphs which illustrate the pharmacological characterization of DGPP 8:0 on the LPA-elicited CI " currents in Xenopus oocytes.
- Oocytes were exposed to a 5 nM concentration of LPA 18:1 mixed with increasing concentrations of DGPP 8:0 and the peak amplitude of the resulting oscillatory CI " cu ⁇ ents were measured (33A).
- Oocytes were exposed to increasing concentrations of
- LPA 18:1 mixed with a 200 nM concentration of DGPP 8:0 (33B).
- Data points represent the average values of a minimum of three measurements ⁇ S.D.
- Oocytes were treated with 5 nM LPA 18:1, or a mixture of 5 nM LPA 18:1 and 1 ⁇ M DGPP 8:0 as indicated (33C).
- the intracellular injection of 1 ⁇ M DGPP 8:0 is indicated by the a ⁇ ow.
- Figures 34A-D are graphs which illustrate DGPP 8:0 inhibiting the LPA-elicited Ca 2+ responses in NIH3T3 fibroblasts and HEY ovarian cancer cells.
- RT-PCR analysis of NIH3T3 cells for Edg and PSP24 receptor transcripts 34A.
- NIH3T3 cells were exposed to a 100 nM concentration of LPA 18:1, or SIP, mixed with a 10 ⁇ M concentration of DGPP 8:0 (34B).
- RT-PCR analysis of HEY cells for the presence of the Edg and PSP24 transcripts 34C.
- HEY cells were exposed to a 100 nM concentration of LPA 18 : 1 , or S 1 P, mixed with a 1 ⁇ M concentration of
- Figure 35 is a graph illustrating DGPP 8:0 inhibition of LPA-elicited proliferation of NIH3T3 cells.
- NIH3T3 cells were serum-starved for 6 hr and exposed to a 5 ⁇ M concentration of LPA 18:1 mixed with a 10 ⁇ M concentration of the indicated lipids.
- Control cells received solvent (BSA) in place of LPA 18:1. The cells were incubated for 24 hr with the lipids and counted. Data are representative of three experiments.
- Figure 36 is a graph which illustrates the pharmacological characterization of the inhibition of the LPA response by straight-chain fatty acid phosphate compounds 106-110 in Xenopus oocytes.
- Figure 37 is a graph which illustrates the pharmacological characterization of the inhibition of the LPA response by straight-chain fatty acid phosphate compound 108 in Xenopus oocytes.
- Figure 38 is a graph illustrating the pharmacological characterization of the antagonist or agonist induced response of RH7777 cells inidividually expressing Edg-2, Edg-4, or Edg-7 receptors, following exposure of the cells to straight-chain fatty acid phosphate compound 108. Peak areas of the Ca responses were measured.
- One aspect of the present invention relates to a compound according to formula (I)
- At least one of X 1 , X 2 , and X 3 is (HO) 2 PO— Z — or (HO) 2 PO— Z 2 — P(OH)O— Z 1 —, X 1 and X 2 are linked together as — O— PO(OH O— , or X 1 and X 3 are linked together as — O— PO(OH)— NH— ; at least one of X , X , and X J is R 1 — Y7-1 — A— with each being the same or different when two of X , X , and X are or X and X 3 are linked together as — N(H)— C(O)— N(R' optionally, one of X 1 , X 2 , and X 3 is H;
- A is either a direct link, (CH 2 ) t with k being an integer from 0 to 30, or O;
- Y 1 is — (CH 2 ) / — with / being an integer from 1 to 30, — O — ,
- Z 1 is — (CH 2 ) TO — or — O(CH 2 ) m — with m being an integer from 1 to 50, — C(R )H— , -NH- -O— , or
- R for each of X , X , or X , is independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri- substitutions of the ring, an acyl including a CI to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, an aryloxyalkyl including straight or branched-chain CI to C30 alkyl,
- R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri- substitutions of the ring, an acyl including a CI to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, or an aryloxyalkyl including straight or branched-chain CI to C30 alkyl.
- Aromatic or heteroaromatic rings include, without limitation, phenyls, indenes, py ⁇ oles, imidazoles, oxazoles, pyrrazoles, pyridines, pyrimidines, py ⁇ olidines, piperidines, thiophenes, furans, napthals, bi-phenyls, and indoles.
- the aromatic or heteroaromatic rings can include mono-, di-, or tri-substitutions of the ring located at the ortho, meta, or para positions on the rings relative to where the ring binds to the Y 1 group of the R 1 — Y 1 — A — chain. Substitutions on the rings can include, without limitation, alkyl, alkoxy, amine (including secondary or tertiary amines), alkylamine, amide, alkylamide, acids, alcohols.
- Acyl groups can include either alkyl, alkenyl, or aromatic or heteroaromatic rings as described above.
- Arylalkyl and aryloxyalkyl groups can include, without limitation, straight or branched-chain CI to C30 alkyl groups as described above, with the alkyl group binding to the Y 1 group of the R 1 — Y 1 — A — chain.
- lysophosphatidic acid phosphatidic acid, cyclic phosphatidic acid, alkenyl glyerolphosphate, dioctyl-glycerol pyrophosphate, and N-palmitoyl-L- serine.
- Exemplary compounds according to formula (I) are the subclass compounds according to formulae (II)-(V) below.
- Q 1 and Q 2 are both H 2 ; one of X 1 , X 2 , and X 3 is (HO) 2 PO— Z 2 — P(OH)O— Z 1 — , with Z 1 and Z 2 being O; and two of X 1 , X 2 , and X 3 are R 1 — Y 1 — A— , with A being a direct link and Y 1 being O for each.
- Each R 1 is defined independently as above for formula (I).
- Each R 1 is defined independently as above for formula (I).
- Prefe ⁇ ed species of within the scope of formula III are where X 3 is — NH 2 and X 2 is —NHR 1 with R 1 being a C14 to C18 alkyl, more preferably either a C14 alkyl or a C18 alkyl; or where X 3 is — NHR 1 with R 1 being an acetyl group and
- X 2 is NHR 1 with R 1 being a C14 alkyl.
- Q 1 and Q 2 are both H 2 ; two of X 1 , X 2 , and X 3 are (HO) 2 PO— Z 1 — , with Z 1 being O for each; and one of X 1 , X 2 , and X 3 is R 1 — Y 1 — A— , with A being a direct link and Y 1 being — O— .
- R 1 is as defined above for formula (I).
- Prefe ⁇ ed species within the scope of formulae (V)A and (V)B include the compounds where R 1 is an acyl including a C21 alkyl or where R 1 is a CI 8 alkyl.
- Figure 5B illustrates the synthesis of 1,3-biphosphates.
- Commercially available 2-phenoxy-l,3-propane-diol was used as the starting material.
- the starting compound was first protected with t- BuOK in the presence of methyl iodide, followed by catalytic hydrogenation to give an intermediate which was then reacted with a halide (RX, where R is as defined above for R 1 ).
- RX halide
- the recovered intermediate was subsequently treated with A1C1 3 in the presence of ethyl-SH to yield a 1,3 diol possessing the RO group bound to C2 of the backbone.
- the recovered 1,3 diol was dissolved in freshly distilled 1:1 THF/CH C1 2 , followed by the addition of lH-tetrazole. To this sti ⁇ ed mixture was added dibenzyldiisopropyl phosphoramidate. The reaction mixture was monitored via TLC, and at the appropriate time the phosphonate was oxidized to the phosphate in situ with peracetic acid. The reaction mixture was purified with column chromatography to afford benzyl-protected bisphosphate compounds. Removal of the protecting benzyl groups was carried out in ethanol by subjecting the compounds to catalytic reduction using 10% palladium on activated carbon (Pd/C) under H atmosphere at 60 psi to yield 1,3-bisphosphate compounds.
- Pd/C palladium on activated carbon
- the benzyl protecting group was removed by hydrogenation and the subsequent hydroxyl group was tosylated by the action of pyridine and >-toluenesulfonyl chloride, producing a di-ether bearing a tosyl group at the C2 position.
- the tosylate group was removed by nucleophilic attack upon treatment with tris(tetra-n-butylammonium) hydrogen pyrophosphate, replacing the tosylate with a pyrophosphate substituent at the C2 position.
- FIGS 15 and 16 Alternative schemes for preparing phosphates and biphosphates (as well as pyrophosphates, phosphonates, etc.) are illustrated in Figures 15 and 16.
- glycidal bromide was used as the starting material along with an alcohol (ROH).
- the reaction conditions included treatment with K 2 CO 3 followed by treatment with the ammonium salt C 6 H 6 CH 2 N + (C 2 Hs) 3 Cr, resulting in displacement of the bromide with the R group.
- the ring of the glycidal intermediate was then opened following treatment with 1M HCl in ether and an alcohol tT OH), which afforded a di-ether intermediate having a hydroxy group at the C2 postion.
- the di-ether was mixed with lH-tetrazole and to this sti ⁇ ed mixture was added dibenzyldiisopropyl phosphoramidate.
- the reaction mixture was monitored via TLC, and at the appropriate time the phosphonate was oxidized to the phosphate in situ with peracetic acid.
- the reaction mixture was purified with column chromatography to afford benzyl-protected phosphates.
- the removal of the protecting benzyl groups was carried out in ethanol by subjecting the benzyl-protected phosphates to catalytic reduction using 10% palladium on activated carbon (Pd/C) under H atmosphere at 60 psi to yield monophosphate compounds.
- the reaction conditions included treatment with K 2 CO 3 followed by treatment with the ammonium salt C 6 H 6 CH 2 N + (C 2 H 5 ) 3 C1 " , resulting in displacement of the bromide with the Bn group.
- the ring of the glycidal intermediate was then opened following treatment with IM HCl in ether and annhydrous BnOH, which protected the CI site.
- the resulting di-ether intermediate has a hydroxy group at the C2 postion.
- the di-ether was mixed with a halide salt (RX) in aqueous K 2 CO 3 , yielding a protected intermediate having an R group attached via ether bond at the C2 position.
- RX halide salt
- This intermediate was de-protected via catalytic reduction using 10% palladium on activated carbon (Pd/C) under H 2 atmosphere at 60 psi to yield a 1,3 diol.
- the diol was combined with lH-tetrazole and to this sti ⁇ ed mixture was added dibenzyldiisopropyl phosphoramidate.
- the reaction mixture was monitored via TLC, and at the appropriate time the phosphonate was oxidized to the phosphate in situ with peracetic acid.
- the reaction mixture was purified with column chromatography to affords benzyl-protected phosphates.
- the removal of the protecting benzyl groups was carried out in ethanol by subjecting the benzyl-protected phosphates to catalytic reduction using 10% palladium on activated carbon (Pd/C) under H 2 atmosphere at 60 psi to yield 1,3 bisphosphates.
- Pd/C palladium on activated carbon
- a number of modified phosphates and phosphonates can be attached at the CI site upon removal of the tosyl group.
- the intermediate is reacted under basic conditions with X 4 — Z 1 — PO(O — protecting group) 2 where Z 1 is — (R 3 )CH — and X 4 is H.
- the basic conditions remove the tosylate protecting group and allow the modified phosphate — Z 1 — PO(O — protecting group) 2 to form a single bond to the CI site.
- the protecting groups are removed following treatment with TMSBr, affording a — (R 3 )CH — PO(OH) 2 group at the CI site.
- the intermediate is reacted under basic conditions using tris(tetra-n-butylammonium) with X 4 — Z 1 — PO(OH)— Z 2 — PO(OH) 2 where Z 1 is — O — , Z 2 is — CH 2 — , and X 4 is H.
- the basic conditions remove the tosylate protecting group and allow the modified phosphonate
- a scheme is shown for preparing a cyclic phosphate where X 1 and X 3 together are — O— PO(OH)— NH — .
- X 1 and X 3 together are — O— PO(OH)— NH — .
- they are treated with tris(l,2,4,-triazole)phosphate followed by 2% HCl wash, resulting in intramolecular cyclization.
- a scheme is shown for preparing a cyclic compound where the phosphate group is not a part of the ring; specifically, X 2 and X 3 together are — N(H) — C(O) — N(R ! ) — .
- intermediates 50-54 Using the intermediates 50-54 prepared above as starting materials, they are treated with anhydrous COCl 2 , which inserts a carbonyl between between the amines bound to the C2 and C3 carbons during cyclization. Benzyl protecting groups are removed from the phosphate using 10% palladium on activated carbon (Pd/C) under H 2 atmosphere (as described above).
- Another class of compounds which can be used as agonists or antagonists of the LPA receptors are fatty acid phosphates or straight-chain phosphates.
- anhydrous n-alkanol and lH-tetrazole can be dissolved in anhydrous methylene chloride.
- a solution of dibenzyl-N,N-diisopropyl phosphoramidite in anhydrous methylene chloride can be added.
- peracetic acid in anhydrous methylene chloride can be added dropwise to afford the benzyl-protected fatty acid phosphates 101-105.
- benzyl-protecting groups are removed following treatment in anhydrous methanol with 10% palladium on activated carbon (Pd/C) under ⁇ 2 atmosphere (as described above), affording the fatty acid phosphates 106-110.
- thiophosphates and amidophosphates can also be prepared. As shown in Figure 9, for example, n- mercaptoalkanes and lH-tetrazole can be dissolved in anhydrous methylene chloride. A solution of dibenzyl-N,N-diisopropyl phosphoramidite in anhydrous methylene chloride can be added.
- peracetic acid in anhydrous methylene chloride can be added dropwise to afford the benzyl-protected fatty acid thiophosphates.
- the benzyl-protecting groups are removed following treatment in anhydrous methanol with 10% palladium on activated carbon (Pd/C) under ⁇ 2 atmosphere (as described above), affording the fatty acid thiophosphates.
- Pd/C palladium on activated carbon
- an n- alkylamine and lH-tetrazole can be dissolved in anhydrous methylene chloride.
- a solution of dibenzyl-N,N-diisopropyl phosphoramidite in anhydrous methylene chloride can be added.
- peracetic acid in anhydrous methylene chloride can be added dropwise to afford the benzyl-protected fatty acid amidophosphates.
- the benzyl-protecting groups are removed following treatment in anhydrous methanol with 10% palladium on activated carbon (Pd/C) under ⁇ 2 atmosphere (as described above), affording the fatty acid amidophosphates.
- reaction schemes can be further modified by attacking a primary amine group as shown in Figures 17-20.
- the intermediate is prepared, e.g., from compounds 50-54 which were treated with TFA to remove the t- Boc protecting group, affording the primary amine at the C2 site while leaving the phosphate protected.
- the intermediate compound possessing a primery amine at the C2 position is attacked with an acid halide (e.g., R'COCl), which converts the primary amine into an amide ( — N(H) — C(O) — R 1 ).
- R'COCl acid halide
- the benzyl-protected phosphate can then be de-protected using treatment with 10% palladium on activated carbon
- the intermediate compound possessing a primery amine at the C2 position is attacked with N-acetyl imidazoline in POCl , which converts the primary amine into a secondary amine ( — N(H) — imidazole).
- N-acetyl imidazoline in POCl , which converts the primary amine into a secondary amine ( — N(H) — imidazole).
- Substituted imidazolines can also be used.
- the benzyl-protected phosphate can then be de- protected using treatment with 10% palladium on activated carbon (Pd/C) under H 2 atmosphere (as described above).
- the intermediate compound possessing a primery amine at the C2 position is attacked with R 1 OC(O)Cl, which converts the primary amine into an carbamate ( — N(H) — C(O) — O — R 1 ).
- the benzyl-protected phosphate can then be de- protected using treatment with 10% palladium on activated carbon (Pd/C) under H 2 atmosphere (as described above).
- the intermediate compound possessing a primery amine at the C2 position is attacked with R'NCO or R ⁇ CS, which converts the primary amine into either a uramide (— N(H)— C(O)— N(H)— R 1 ) or thiouramide (— N(H)— C(S)— N(H) — R 1 ).
- R'NCO or R ⁇ CS converts the primary amine into either a uramide (— N(H)— C(O)— N(H)— R 1 ) or thiouramide (— N(H)— C(S)— N(H) — R 1 ).
- the benzyl-protected phosphate can then be de-protected using treatment with 10%) palladium on activated carbon (Pd/C) under H 2 atmosphere (as described above).
- the non-cyclic compounds of the present invention can be prepared by reacting (Y 2 O) 2 PO— Z n — Z 13 or (Y 2 O) 2 PO— Z 12 — P(OH)O— Z n — Z 13 , where Z 11 is — (CH 2 ) m — or — O(CH ) m — with m being an integer from 1 to 50, — C(R 3 )H— , or — O— , Z 12 is — (CH 2 ) complicat— or — O(CH 2 ) admir— with n being an integer from 1 to 50 or — O — , Z 13 is H or a first leaving group or — Z u — Z 13 together form the first leaving group, and Y 2 is H or a protecting group; with an intermediate compound according to formula (VI), followed by a de-protection step, if necessary, both performed under conditions effective to afford a compound according to formula (I) where one or two ofX ⁇ X 2 , and X 3
- the intermediate compound of formula (VI) has the following structure:
- NI wherein, at least one of X 11 , X 12 , and X 13 is R 11 — Y 11 — A— with each being the same or different when two of X 11 , X 12 , and X 13 are R n — Y 11 — A — , or X 12 and X 13 are linked together as — ⁇ (H)— C(O)— ⁇ (R n )— ; at least one of X 1 ', X 12 , and X 13 is OH, NH 2 , SH, or a second leaving group; optionally, one of X n , X 12 , and X 13 is H;
- A is either a direct link, (CH 2 )* with k being an integer from 0 to 30, or O;
- Y ⁇ is — (CH 2 ) / — with / being an integer from 1 to 30, — O — , O
- R 11 for each of X 11 , X 12 , or X 13 , is independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri- substitutions of the ring, an acyl including a CI to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, an aryloxyalkyl including straight or branched-chain CI to C30 alkyl,
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently hydrogen, a straight or branched-chain CI to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a CI to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain CI to C30 alkyl, or an aryloxyalkyl including straight or branched-chain CI to C30 alkyl.
- a further aspect of the present invention relates to a pharmaceutical composition that includes a pharmaceutically-acceptable carrier and a compound of the present invention.
- the pharmaceutical composition can also include suitable excipients, or stabilizers, and can be in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions.
- the composition will contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the carrier, excipient, stabilizer, etc.
- the solid unit dosage forms can be of the conventional type.
- the solid form can be a capsule, such as an ordinary gelatin type containing the compounds of the present invention and a carrier, for example, lubricants and inert fillers such as, lactose, sucrose, or comstarch.
- these compounds are tableted with conventional tablet bases such as lactose, sucrose, or comstarch in combination with binders like acacia, comstarch, or gelatin, disintegrating agents, such as comstarch, potato starch, or alginic acid, and a lubricant, like stearic acid or magnesium stearate.
- the compounds of the present invention may also be administered in injectable or topically-applied dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical carrier.
- a pharmaceutical carrier include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers.
- Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
- water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol are prefe ⁇ ed liquid carriers, particularly for injectable solutions.
- the compounds of the present invention in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
- suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
- the materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
- the compounds of the present invention can be administered orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.
- compositions within the scope of this invention include all compositions wherein the compound of the present invention is contained in an amount effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise about 0.01 to about 100 mg/kg body wt. The prefe ⁇ ed dosages comprise about 0.1 to about 100 mg/kg-body wt. The most prefe ⁇ ed dosages comprise about 1 to about 100 mg/kg-body wt. Treatment regimen for the administration of the compounds of the present invention can also be determined readily by those with ordinary skill in art.
- Certain compounds of the present invention have been found to be useful as agonists of LPA receptors while other compounds of the present invention have been found useful as antagonists of LPA receptors. Due to their differences in activity, the various compounds find different uses.
- the prefe ⁇ ed animal subject of the present invention is a mammal, i.e., an individual belonging to the class Mammalia.
- the invention is particularly useful in the treatment of human subjects.
- One aspect of the present invention relates to a method of modulating
- LPA receptor activity which includes providing a compound of the present invention which has activity as either an LPA receptor agonist or an LPA receptor antagonist and contacting an LPA receptor with the compound under conditions effective to modulate the activity of the LPA receptor.
- the LPA receptor is present on a cell which either normally expresses the LPA receptor or has otherwise been transformed to express a particular LPA receptor. Suitable LPA receptors include, without limitation, EDG-2, EDG-4, EDG-7, and PSP-24 receptors.
- the tissues which contain cells that normally express these receptors are indicated in Table 1 above.
- a nucleic acid molecule encoding one or more of such receptors can be inserted in sense orientation into an expression vector which includes appropriate transcription and translations regulatory regions (i.e., promoter and transcription termination signals) and then host cells can be transformed with the expression vector.
- the expression vector may integrate in the cellular genome or simply be present as extrachromosomal nuclear material. Expression can be either constitutive or inducible, although constitutive expression is suitable for most purposes.
- EDG-2 The nucleotide and amino acid sequences for EDG-2 is known and reported in An et al. (1997b) and Genbank Accession No. U80811, which is hereby incorporated by reference.
- An EDG-2 encoding nucleic acid molecule has a nucleotide sequence according to SEQ. TD. No. 1 as follows:
- the encoded EDG-2 receptor has an amino acid sequence according to SEQ. ID. No. 2 as follows:
- IPSVGWNCIC DIENCSN AP LYSDSY VFW AIFN VTFW MWLYAHIFG YVRQRT RMS 240
- EDG-4 The nucleotide and amino acid sequences for EDG-4 is known and reported in An et al. (1998b) and Genbank Accession No. NM_004720, which is hereby incorporated by reference.
- An EDG-4 encoding nucleic acid molecule has a nucleotide sequence according to SEQ. ID. No. 3 as follows:
- the encoded EDG-4 receptor has an amino acid sequence according to SEQ. ID. No. 4 as follows:
- EDG-7 The nucleotide and amino acid sequences for EDG-7 is known and reported in Bandoh et al. (1999) and Genbank Accession No. NM_012152, which is hereby incorporated by reference.
- An EDG-7 encoding nucleic acid molecule has a nucleotide sequence according to SEQ. ID. No.5 as follows:
- the encoded EDG-7 receptor has an amino acid sequence according to SEQ. ID. No.6 as follows:
- a PSP-24 encoding nucleic acid molecule has a nucleotide sequence according to SEQ. ID. No.7 as follows:
- the encoded PSP-24 receptor has an amino acid sequence according to SEQ. ID. No. 8 as follows:
- LPA receptor agonists will characteristically induce LPA-like activity from an LPA receptor, which can be measured either chemically, e.g., Ca 2+ or CI " cu ⁇ ent in oocytes, or by examining changes in cell morphology, mobility, proliferation, etc.
- LPA receptor antagonists will characteristically block LPA-like activity from an LPA receptor. This too can be measured either chemically, ' e.g., Ca 2+ or CI " cu ⁇ ent in oocytes, or by examining changes in cell morphology, mobility, proliferation, etc.
- the present invention also relates to a method of inhibiting LPA- induced activity on an LPA receptor.
- This method includes providing a compound of the present invention which has activity as an LPA receptor antagonist and contacting an LPA receptor with the compound under conditions effective to inhibit LPA-induced activity of the LPA receptor.
- the LPA recepter can be as defined above.
- the LPA receptor is present on a cell which normally expresses the receptor or which heterologously expresses the receptor.
- the contacting of the LPA receptor with the compound of the present invention can be performed either in vitro or in vivo.
- LPA is a signaling molecule involved in a number of different cellular pathways which involve signaling through LPA receptors, including those LPA receptors described above. Therefore, it is expected that the compounds of the present invention will modulate the effects of LPA on cellular behavior, either by acting as LPA receptor antagonists or LPA receptor agonists.
- One aspect of the present invention relates to a method of treating cancer which includes providing a compound of the present invention and administering an effective amount of the compound to a patient in a manner effective to treat cancer.
- the types of cancer which can be treated with the compounds of the present invention includes those cancers characterized by cancer cells whose behavior is attributable at least in part to LPA-mediated activity.
- these types of cancer are characterized by cancer cells which express one or more types of LPA receptors.
- exemplary forms of cancer include, without limitation, prostate cancer and ovarian cancer.
- the compounds of the present invention which are particularly useful for cancer treatment are the LPA receptor antagonists.
- administering When administering the compounds of the present invention, they can be administered systemically or, alternatively, they can be administered directly to a specific site where cancer cells are present. Thus, administering can be accomplished in any manner effective for delivering the compound to cancer cells. Without being bound by theory, it is believed that the LPA receptor antagonists, upon binding to LPA receptors, will inhibit proliferation or metastasis of the cancer cells or otherwise destroy those cancer cells. As shown in Example 12 infra, several LPA antagonist compounds of the present invention were cytotoxic to prostate cancer cell lines which express one or more LPA receptors of the type described above.
- the pharmaceutical composition can also contain, or can be administered in conjunction with, other therapeutic agents or treatment regimen presently known or hereafter developed for the treatment of various types of cancer.
- Cancer invasion is a complex multistep process in which individual cells or cell clusters detach from the primary tumor and reach the systemic circulation or the lymphatics to spread to different organs (Liotta et al., 1987). During this process, tumor cells must arrest in capillaries, extravasate, and migrate into the stroma of the tissue to make secondary foci. First, tumor cells must recognize signals on the endothelial cell that arrest them from the circulation. Second, tumor cells must attach to the basement membrane glycoprotein laminin via the cell surface laminin receptors. Following attachment to the basement membrane, tumor cells secrete proteases to degrade the basement membrane. Following attachment and local proteolysis, the third step of invasion is tumor cell migration.
- LNCaP cells LNCaP cells.
- RT-PCR analysis on the prostate cancer cell lines DU-145, PC-3, and LNCaP lines showed that EDG-2, 4, 5, and EDG-7 are present in all three prostate cancer cell lines, whereas EDG-3 is present in LNCaP and DU-145 prostate cancer cell lines.
- LPA antagonists of the present invention provide an alternative approach for treatment of LPA-mediated cancers, including prostate cancer and ovarian cancer.
- Another aspect of the present invention relates to a method of enhancing cell proliferation. This method of enhancing cell proliferation includes the steps of providing a compound of the present invention which has activity as an agonist of an LPA receptor and contacting the LPA receptor on a cell with the compound in a manner effective to enhance LPA receptor-induced proliferation of the cell.
- LPA In addition to the roles that LPA plays in modulating cancer cell activity, there is strong evidence to suggest that LPA also has a physiological role in natural wound healing.
- LPA derived from activated platelets is believed to be responsible, at least in part, for stimulating cell proliferation at the site of injury and inflammation possibly in synchronization with other platelet-derived factors (Balazs et al., 2000).
- LPA by itself stimulates platelet aggregation, which may in turn be the factor that initiates an element of positive feedback to the initial aggregatory response (Schumacher et al., 1979; Tokumura et al., 1981; Ge ⁇ ard et al., 1979; Simon et al., 1982).
- Another aspect of the present invention relates to a method of treating a wound. This method is carried out by providing a compound of the present invention which has activity as an agonist of an LPA receptor and delivering an effective amount of the compound to a wound site, where the compound binds to LPA receptors on cells that promote healing of the wound, thereby stimulating LPA receptor agonist-induced cell proliferation to promote wound healing.
- Open cutaneous wounds represent one major category of wounds and include bum wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers. Open cutaneous wounds routinely heal by a process which comprises six major components: i) inflammation, ii) fibroblast proliferation, iii) blood vessel proliferation, iv) connective tissue synthesis v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Numerous factors can affect wound healing, including malnutrition, infection, pharmacological agents (e.g., actinomycin and steroids), diabetes, and advanced age (see Hunt and Goodson, 1988).
- pharmacological agents e.g., actinomycin and steroids
- Phospholipids have been demonstrated to be important regulators of cell activity, including mitogenesis (Xu et al., 1995b), apoptosis, cell adhesion, and regulation of gene expression. Specifically, for example, LPA elicits growth factorlike effects on cell proliferation (Moolenaar, 1996) and cell migration (Imamura et al., 1993). It has also been suggested that LPA plays a role in wound healing and regeneration (Tigyi and Miledi, 1992).
- agents which promote a more rapid influx of fibroblasts, endothelial and epithelial cells into wounds should increase the rate at which wounds heal.
- Compounds of the present invention that are useful in treating wound healing can be identified and tested in a number of in vitro and in vivo models.
- tissue culture cells such as fibroblasts (Verrier et al., 1986), endothelial cells (Miyata et al., 1990) or epithelial cells (Kartha et al., 1992).
- Other systems permit the measurement of endothelial cell migration and/or proliferation (Muller et al., 1987; Sato et al.,
- wound healing In vivo models for wound healing are also well-known in the art, including wounded pig epidermis (Ohkawara et al., 1977) or drug-induced oral mucosal lesions in the hamster cheek pouch (Che ⁇ ck et al., 1974).
- the compounds of the present invention which are effective in wound healing can also be administered in combination, i.e., in the pharmaceutical composition of the present invention or simultaneously administered via different routes, with a medicament selected from the group consisting of an antibacterial agent, an antiviral agent, an antifungal agent, an antiparasitic agent, an antiinflammatory agent, an analgesic agent, an antipruritic agent, or a combination thereof.
- a prefe ⁇ ed mode of administration is by the topical route.
- the agent may be administered by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal or transdermal routes.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concu ⁇ ent treatment, if any, frequency of treatment, and the nature of the effect desired.
- prefe ⁇ ed topical applications especially for treatment of humans and animals having a wound, it is prefe ⁇ ed to administer an effective amount of a compound according to the present invention to the wounded area, e.g., skin surfaces.
- This amount will generally range from about 0.001 mg to about 1 g per application, depending upon the area to be treated, the severity of the symptoms, and the nature of the topical vehicle employed.
- a prefe ⁇ ed topical preparation is an ointment wherein about 0.01 to about 50 mg of active ingredient is used per ml of ointment base, such as PEG- 1000.
- the present invention further provides methods of inhibiting apoptosis or preserving or restoring cell, tissue or organ function.
- This method is carried out by providing a compound of the present invention which has activity as an agonist of an LPA receptor and contacting a cell, tissue, or organ with an amount of the compound which is effective to treat apoptosis, or preserve or restore function in the cell, tissue, or organ.
- the contacting can be carried out in vitro (i.e., during cell culture or organ or tissue transfer) or in vivo (i.e., by administering the effective amount of the compound to a patient as indicated below).
- Various indications which can be treated include, but are not limited to, those related to apoptosis, ischemia, traumatic injury and reperfusion damage.
- Those conditions related to apoptosis include, but are not limited to, dermatological effects of aging, the effects of reperfusion after an ischemic event, immunosuppression, gastrointestinal perturbations, cardiovascular disorders, rejection of tissue transplantation, wound healing, and Alzheimer's disease.
- the treatment can also diminish the apoptosis-related problems associated with immunosuppressing viruses, chemotherapeutic agents, or radiation and immunosuppressive drugs.
- the treatments are also suitable during all phases of organ transplantation.
- the compounds having agonist activity on an LPA receptor can be used to prepare the organ by administering an amount of the compound to the donor effective to stabilize or preserve the organ.
- the organ can be perfused and/or preserved in OPS containing the compound.
- the organ recipient can then be administered an amount of the compound effective to enhance organ stability and function.
- the compositions are also particularly suitable for use in treating cardioplegia, whether related to transplantation or other surgical intervention.
- Apoptosis related problems are caused by a variety of stimuli which include, but are not limited to, viruses including, but not limited to, HIV, chemotherapeutic agents, and radiation. These stimuli trigger apoptosis in a variety of disorders, including, but not limited to, those of the digestive tract tissues and associated gastrointestinal perturbations.
- Gastrointestinal perturbations include, but are not limited to, damage to the lining of the gut, severe chronic ulcers, colitis, radiation induced damage, chemotherapy induced damage, and the perturbation of the gastrointestinal tract caused by parasites, and diarrhea from any other cause.
- Various viral and bacterial infections are known to result in gastrointestinal perturbations.
- the compounds having agonist activity on an LPA receptor are also suitable for use in treatment of the side effects associated with these infections.
- Such compounds are particularly suited for use in ameliorating the gastrointestinal disturbances associated with chemotherapy.
- such compounds are suitable for use not only in preventing the dia ⁇ hea associated with chemotherapy but also the nausea.
- gastrointestinal conditions are particularly suited to treatment of various gastrointestinal conditions in animals, including, but not limited to livestock and domesticated animals. Such conditions, particularly dia ⁇ hea, account for the loss of many calves and puppies to dehydration and malnutrition.
- Treatment of gastrointestinal conditions is preferably by gastrointestinal administration. In the case of cattle and domesticated animals, an effective amount of these compounds can be conveniently mixed in with the feed. In humans, administration can be by any method known in the art of gastrointestinal administration. Preferably, administration is oral.
- the compounds having agonist activity on an LPA receptor can be administered to immunodeficient patients, particularly HIV-positive patients, to prevent or at least mitigate apoptotic death of T cells associated with the condition, which results in the exacerbation of immunodeficiencies as seen in patients with AIDS.
- administration to such patients is parenterally, but can also be transdermally or gastrointestinally.
- the compounds having agonist activity on an LPA receptor can also be administered to treat apoptosis associated with reperfusion damage involved in a variety of conditions, including, but not limited to, coronary artery obstruction; cerebral infarction; spinal/head trauma and concomitant severe paralysis; reperfusion damage due to other insults such as frostbite, coronary angioplasty, blood vessel attachment, limb attachment, organ attachment and kidney reperfusion.
- Myocardial and cerebral infarctions are caused generally by a sudden insufficiency of arterial or venous blood supply due to emboli, thrombi, or pressure that produces a macroscopic area of necrosis; the heart, brain, spleen, kidney, intestine, lung and testes are likely to be affected.
- Cell death occurs in tissue su ⁇ ounding the infarct upon reperfusion of blood to the area; thus, the compositions are effective if administered at the onset of the infarct, during reperfusion, or shortly thereafter.
- the present invention includes methods of treating reperfusion damage by administering a therapeutically effective amount of the compounds having agonist activity on an LPA receptor to a patient in need of such therapy.
- the invention further encompasses a method of reducing the damage associated with myocardial and cerebral infarctions for patients with a high risk of heart attack and stroke by administering a therapeutically effective amount of the compounds having agonist activity on an LPA receptor to a patient in need of such therapy.
- treatment of such damage is by parenteral administration of such compounds.
- Any other suitable method can be used, however, for instance, direct cardiac injection in the case of myocardial infarct. Devices for such injection are known in the art, for instance the Aboject cardiac syringe.
- the invention further provides methods of limiting and preventing apoptosis in cells, or otherwise preserving cells, during the culture or maintenance of mammalian organs, tissues, and cells, by the addition of an effective amount of the compounds having agonist activity on an LPA receptor to any media or solutions used in the art of culturing or maintaining mammalian organs, tissues, and cells.
- the invention further encompasses media and solutions known in the art of culturing and maintaining mammalian organs, tissues and cells, which include an amount of the compounds having agonist activity on an LPA receptor which is effective to preserve or restore cell, tissue or organ function, or limit or prevent apoptosis of the cells in culture.
- These aspects of the invention encompass mammalian cell culture media including an effective amount of at least one compounds having agonist activity on an LPA receptor and the use of such media to preserve or restore cell, tissue or organ function, or to limit or prevent apoptosis in mammalian cell culture.
- An effective amount is one which decreases the rate of apoptosis and/or preserves the cells, tissue or organ.
- Such compounds can limit or prevent apoptosis under circumstances in which cells are subjected to mild traumas which would normally stimulate apoptosis.
- exemplary traumas can include, but are not limited to, low level i ⁇ adiation, thawing of frozen cell stocks, rapid changes in the temperature, pH, osmolarity, or ion concentration of culture media, prolonged exposure to non-optimal temperature, pH, osmolarity, or ion concentration of the culture media, exposure to cytotoxins, disassociation of cells from an intact tissue in the preparation of primary cell cultures, and serum deprivation (or growth in serum- free media).
- the invention encompasses compositions comprising tissue culture medium and an effective amount of the compounds having agonist activity on an LPA receptor.
- Serum-free media to which the compositions can be added as anti- apoptotic media supplements include, but are not limited to, AIM V(P Media, Neuman and Tytell's Serumless Media, Trowell's T8 Media, Waymouth's MB 752/1 and 705/1 Media, and Williams' Media E.
- suitable mammalian cell culture media to which the compounds having agonist activity on an LPA receptor can be added as anti-apoptotic media supplements include, but are not limited to, Basal Media Eagle's, Fischer's Media, McCoy's Media, Media 199, RPMI Media 1630 and
- Mammalian cell culture media to which the compounds having agonist activity on an LPA receptor can be added further include any media supplement known in the art.
- Exemplary supplmenets include, but are not limited to, sugars, vitamins, hormones, metalloproteins, antibiotics, antimycotics, growth factors, lipoproteins, and sera.
- the invention further encompasses solutions for maintaining mammalian organs prior to transplantation, which solutions include an effective amount of the compounds having agonist activity on an LPA receptor, and the use of such solutions to preserve or restore organ function or to limit or prevent apoptosis in treated mammalian organs during their surgical removal and handling prior to transplantation.
- the solutions can be used to rush, perfuse and/or store the organs.
- concentrations of the compounds (having agonist activity on an LPA receptor) required to limit or prevent damage to the organs can be determined empirically by one skilled in the art by methods known in the art.
- the compounds having agonist activity on an LPA receptor can be topically applied to the skin to treat a variety of dermatologic conditions. These conditions include, but are not limited to, hair loss and wrinkling due to age and/or photo damage.
- the present invention also encompasses, therefore, methods of treating dermatological conditions.
- hair loss can be caused by apoptosis of the cells of the hair follicles (Stenn et al., "Expression of the bcl-2 Protooncogene in the Cycling Adult Mouse Hair Follicle," J. Invest. Dermatol. 103: 107-111 (1994), which is hereby incorporated by reference in its entirety). Therefore, the compounds having agonist activity on an LPA receptor are suitable for use in topical treatment of the skin to prevent continued hair loss.
- the various dermatologic conditions are preferably treated by topical application of an effective amount of a compound having agonist activity on an LPA receptor (or compositions which contain them).
- An effective amount of such compounds is one which ameliorates or diminishes the symptoms of the dermatologic conditions.
- the treatment results in resolution of the dermatologic condition or restoration of normal skin function; however, any amelioration or lessening of symptoms is encompassed by the invention.
- mp melting points
- ⁇ and 13 C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AX 300 spectrometer (300, 75.5 MHz). Chemical shift values ( ⁇ ) are expressed as parts per million (ppm) relative to tetramethylsilane (TMS). Peaks are abbreviated as follows: s - singlet; d - doublet; t - triplet; q - quartet; bs - broad singlet; m - multiplet. Proton, carbon- 13, and phosphorous-31 magnetic resonance spectra were obtained on a Bruker AX 300 spectrometer. Chemical shifts for proton and carbon- 13 are reported as parts per million ( ⁇ ) relative to tetramethylsilane (TMS).
- Mass spectra were recorded on either a Bruker Esquire AG or a
- lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Fatty acid-free bovine serum albumin (BSA). Prior to use, LPA was complexed, at a 1:1 ratio molar ratio, with 1 mM BSA dissolved in Ca 2+ -free Hanks' balanced salt solution containing 1 mM EGTA. Aliquots of all the other lipids were dissolved in
- Cytofectene transfection reagent was from Bio-Rad (Hercules, CA). Fura-2 AM was from Molecular Probes (Eugene, OR).
- FBS fetal bovine serum
- G418 were obtained from Cellgro (Hemdon, VA).
- RH7777 cells stably expressing human Edg-4, were kindly provided by Dr. Kevin Lynch (University of Virginia, Charlottesville, VA).
- Flag-tagged cDNA's encoding human Edg-4 and -7 inserted into the pCDNA3 expression plasmid (Invitrogen, Carlsbad, CA), were a generous gift from Dr. Junken Aoki (University of Tokyo, Tokyo, Japan).
- RH7777 and NIH3T3 cells were obtained from the American
- HEY cells were provided by Dr. Lisa Jennings (University of Tennessee, Memphis). All cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% FBS and 2 mM glutamine. Oocytes were obtained from adult Xenopus laevis frogs as previously described (Tigyi et al., 1999).
- DMEM Dulbecco's Modified Eagle's Medium
- RH7777 cells were transfected with the cDNA constructs encoding human Edg-2, Edg-4, or Edg-7 and then were subcloned into the pCDNA3 expression vector using the Cytofectene transfection reagent according to the manufacturers' protocol. Transfected cells were selected in DMEM containing 10% FBS and 1 mg/ml geneticin. Resistant cells were collected and subcloned by limiting dilution. The resulting clones were then screened using functional assays and RT-PCR analysis. Data are representative of three individual clones.
- Data points represent the average of at least 3 measurements ⁇ standard deviation.
- EDG-1 forward primer 5 '- 81 TCATCGTCCGGCATTACAACTA-3 ' (SEQ. ID No. 9); reverse primer 5'-GAGTGAGCTTGTAGGTGGTG 35 ⁇ -3' (SEQ. ID No. 10);
- EDG-5 forward primer 5'- n ATGGGCAGCTTGTACTCGGAG-3' SEQ. ID No. 17
- reverse primer 5'-CAGCCAGCAGACGATAAAGAC 720 -3' SEQ. ID No. 18
- EDG-6 forward primer 5'- 280 TGAACATCACGCTGAGTGACCT-3' (SEQ. ID No. 19); reverse primer 5'-GATCATCAGCACCGTCTTCAGC 790 -3' (SEQ. ID No. 20); EDG-7 forward primer 5'- 9 ⁇ AGCAACACTGATACTGTCGATG-3' (SEQ. ID No. 21); reverse primer 5'-GCATCCTCATGATTGACATGTG 446 -3' (SEQ. ID No. 22);
- EDG-8 forward primer 5'- 88 ATCTGTGCGCTCTATGCAAGGA-3' (SEQ. ID No. 23); reverse primer S'-GGTGTAGATGATAGGATTCAGCA ! ⁇ 6 ⁇ -3' (SEQ. ID No. 24);
- PSP24 forward primer 5'- 320 CTGCATCATCGTGTACCAGAG-3' (SEQ. ID No. 25); and reverse primer 5'-ACGAACTCTATGCAGGCCTCGCn 84 -3' (SEQ. ID No. 26).
- NIH3T3 cells Proliferation of NIH3T3 cells was assessed by direct cell counting as previously described (Tigyi et al., 1999). NIH3T3 cells were plated in 24-well plates at a density of 10,000 cells/well, in DMEM containing 10% FBS. The following day, the cells were rinsed and serum starved in DMEM for 6 hr. Lipids were then added for 24 hr. Cell numbers were determined by counting in a Coulter counter (Coulter
- Example 1 Synthesis of N- rf-butoxycarbonylJ-L-serine ⁇ -lactone, Intermediate Compound 25
- a 500 ml three-neck flask was equipped with a low temperature thermometer and a 100 ml dropping funnel. All glassware were flame-dried and cooled to room temperature under Argon (Ar) before use. To the flask were added triphenylphosphine (Ph 3 P) (10 g, 38 mmol, dried over P O 5 under vacuum for 72 hrs) and freshly distilled THF (190 ml). The solution was cooled and sti ⁇ ed at -78 °C (dry ice-acetone bath) under argon.
- the mixture was sti ⁇ ed overnight at -78 °C under argon and allowed to warm to 0 °C (the flask was placed in an ice bath when the temperature reached -10 °C). After 30 min (ca) the ice bath was replaced with a water bath, and the reaction mixture was sti ⁇ ed for 2 hrs and concentrated on the rotary evaporator to pale yellow oil at 30 °C.
- Example 2 Synthesis of Compounds 26-34
- the glassware used were flame-dried and cooled to room temperature under argon atmosphere. The reaction was carried out in argon atmosphere. THF was freshly distilled prior to use.
- N-(tert-butoxycarbonyl)-L-serine ⁇ -lactone 200 mg, 1.06 mmol was added, and the mixture was refluxed overnight under argon.
- the reaction mixture was concentrated on a rotary evaporator. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- N-(tert-butoxycarbonyl)-L-serine ⁇ -lactone 300 mg, 1.60 mmol was added, and the mixture was refluxed overnight under argon. The reaction mixture was concentrated on a rotary evaporator. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- N-(tert-butoxycarbonyl)-L-serine ⁇ -lactone (91 mg, 0.490 mmol) was added, and the mixture was refluxed for 48 hrs under argon.
- the reaction mixture was concentrated on a rotary evaporator. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- N-(tert-butoxycarbonyl)-L-serine ⁇ -lactone (102 mg, 0.545 mmol) was added, and the mixture was refluxed for 48 hrs under argon.
- the reaction mixture was concentrated on a rotary evaporator. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the glassware used is flame-dried and cooled to room temperature under an argon atmosphere.
- the starting alcohol was washed with anhydrous pyridine (3 times), and dried (high vacuum for 48 hrs).
- the reaction was carried out in an argon atmosphere. THF and CH 2 C1 2 were freshly distilled prior to their use.
- the mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid.
- the THF and CH 2 C1 2 were removed under reduced pressure.
- the concentrate was treated with EtOAc (70 ml), and was washed with Na-metabisulfite (2x25 ml), NaHCO 3 (2x30 ml), water (2x30 ml), and brine (2x30 ml).
- the organic portion was dried over NaSO 4 , and concentrated under reduced pressure. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid.
- the THF and CH 2 C1 2 were removed under reduced pressure.
- the concentrate was treated with EtOAc (70 ml), and was washed with Na-metabisulfite (2x30 ml), NaHCO 3 (2x40 ml), water (2x35 ml), and brine (2x35 ml).
- the organic portion was dried over NaSO 4 , and concentrated under reduced pressure. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the TLC of the reaction mixture showed the formation of the product. This mixture was cooled to 0 °C (ice bath), and a large excess of peracetic acid was added. The mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid. The THF and CH 2 C1 2 were removed under reduced pressure. The concentrate was treated with EtOAc (50 ml), and was washed with Na-metabisulfite (2x25 ml), NaHCU 3 (2x25 ml), water (2x25 ml), and brine (2x25 ml). The organic portion was dried over NaSO , and concentrated under reduced pressure. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid.
- the THF and CH 2 C1 2 were removed under reduced pressure.
- the concentrate was treated with EtOAc (70 ml), and was washed with Na-metabisulfite (2x25 ml), NaHCO 3 (2x35 ml), water (2x35 ml), and brine (2x35 ml).
- the organic portion was dried over NaSO 4 , and concentrated under reduced pressure. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the TLC of the reaction mixture showed the formation of the product. This mixture was cooled to 0 °C (ice bath), and a large excess of peracetic acid was added. The mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid. The THF and CH 2 C1 2 were removed on a rotary evaporator. The concentrate was treated with EtOAc (50 ml), and was washed with Na-metabisulfite (2x15 ml), NaHCO 3
- the mixture was sti ⁇ ed for another 35 mins, followed by the addition of Na-metabisulfite to quench the excess peracetic acid.
- the THF and CH 2 C1 were removed under reduced pressure.
- the concentrate was treated with EtOAc (80 ml), and was washed with Na-metabisulfite (2x35 ml), NaHCO 3 (2x40 ml), water (2x30 ml), and brine (2x30 ml).
- the organic portion was dried over NaSO 4 , and concentrated under reduced pressure. The residue was subjected to flash column chromatography, eluting with EtOAc/hexanes of various compositions.
- the glassware used was flame-dried and cooled to room temperature under an argon atmosphere.
- the starting alcohol was washed with anhydrous pyridine (3 times) and dried on high vacuum for 48 hrs.
- the reaction was carried out in an argon atmosphere. THF and CH 2 C1 were freshly distilled prior to their use.
- Xenopus oocytes which endogenously express PSP24 PLGFR were used to screen the newly designed and synthesized compounds for their LPA inhibitory activity.
- Oocytes were obtained from xylazine-anesthetized adult Xenopus laevis frogs (Carolina Scientific, Burlington, NC) under aseptic conditions and prepared for experiment. Stage V-VI oocytes were denuded of the the follicular cell layer with type A collagenase treatment (Boehringer, IN) at 1.4 mg/ml in a Ca 2+ -free ovarian Ringers- 2 solution ((OR-2) 82.5 mM NaCl, 2 mM KC1, 1 mM MgCl 2 , 5mM HEPES, pH 7.5, with NaOH). Oocytes were kept in Barth's solution in an incubator between 17-20 °C and were used for 2-7 days after isolation.
- type A collagenase treatment Boehringer, IN
- Oocytes were kept in Barth's solution in an incubator between 17-20 °C and were used for 2-7 days after isolation.
- Electrophysiological recordings were carried out using a standard two- electrode voltage-clamp amplifier holding the membrane potential at -60 mV (GeneClamp 500, Axon Instruments, CA). Test compounds were dissolved in MeOH, complexed with fatty acid free BSA, and diluted with frog Na + -Ringers solution (120 nM NaCl, 2 mM KC1, 1.8 mM CaCl 2 , 5 mM HEPES; pH 7.0), which were applied through superfusion to the oocyte at a flow rate of 5 ml/min.
- Membrane currents were recorded with aNIC-310 digital oscilloscope (Nicolet, Madison, Wl). Applications were made at intervals of 15 mins (minimum) to allow for the appropriate washout and recovery from desensitization.
- Figures 21-27 show the dose-dependent inhibition of LPA-induced chloride cu ⁇ ents by compounds 56, 57, 66, and 92.
- Compound 36 was the best inhibitor among the non-phosphorylated derivatives.
- compound 36 was injected intracellularly to see whether its inhibitory effects were a result of its actions on the cell surface or whether the inhibition was a result of its actions within the cell, this intracellular application of 36 did not give any information as to its site of action.
- phosphorylated compounds 55-59 were synthesized to interact on the cell surface and to prevent the compounds from penetrating into the cell.
- Compounds 56, 57, 66, and 92 were inhibitors of LPA-induced chloride cu ⁇ ent in Xenopus oocyte. Compounds 56, 57, 66, and 92 were able to block the actions of LPA in a dose-dependent fashion. Moreover, washing the the Xenopus oocyte, there was a complete recovery of the LPA response; that experiment implies that compounds 56, 57, 66, 92 were able to inhibit the LPA-induced chloride cu ⁇ ents in a reversible fashion. Compound 66 at 5 ⁇ M completely abolished the effect of LPA in Xenopus oocytes, with an IC 50 of about 1.2 ⁇ M ( Figures 23 and 24). Moreover, when 66 was microinjected inside the cell (a ⁇ ow, Figure 23B), followed by the extracellular application of LPA (10 nM), it failed to inhibit the LPA response; that experiment suggests that the inhibitory actions of compound 66 were of an extracellular nature.
- Compound 56a was designed and synthesized to test the importance of the free amino group. When 56a was evaluated in the Xenopus oocyte assay, 56a enhanced the LPA response when applied in combination with LPA. Compound 56a did not elicit a response at 2 ⁇ M (not shown), but at 10 ⁇ M, 56a was able to elicit a response on its own ( Figure 26); that experiment suggests, that a free amino group is necessary for the inhibitory activity.
- HEY ovarian cells were maintained in RPMI 1640 medium with 2 mM L-glutamine (GIBCO BRL) supplemented with 10% fetal bovine serum (FBS, Hyclone). All cells were synchronized to the G 0 /G ⁇ stage by growing them to confluency for 2 days. The cells were replated and harvested for experiments when cells were about 50 -60% confluent on the flask. After removal of the cells from the flask, they were exposed for 5 min to 0.53 mM EDTA in PBS at 37°C. EDTA was neutralized with equal volume of RPMI 1640 plus 2 mM L-glutamine and 10% FBS. Cells were centrifuged at 800 rpm for 10 min at room temperature. Harvested cells were washed twice with RPMI 1640 with 2 mM L-glutamine medium and resuspended in the concentration of 1 xlO 6 cells/ml, and then rested for 1 hr at 37°C.
- a modified quantitative cell migration assay (Cat. # ECM500 from Chemicon, Temecula, CA) was used to test cell motility.
- the Chemicon chamber membrane was coated with fibronectin-containing pores of 8 microns in diameter.
- a 400 ⁇ l RPMI/2 mM L-glutamine containing either no inhibitors or inhibitors (1 ⁇ M) were pippetted into the lower chamber.
- About 5 x 10 4 cells in RPMI 1640/2 mM L- glutamine were added to the top chamber.
- the 24-well plates with inserts were incubated for 4 hours in a 5% CO incubator at 37°C.
- the chambers were removed to a fresh 24-well plate, and the cells on the inside chamber were removed by a swab several times and placed in the prepared Cell Stain Solution for 30 minutes at room temperature. At the end of incubation, Cell Stain Solution was removed from the wells. The chambers were washed 3 times with 1 mL PBS per well. After the final PBS wash, the chambers were examined to confirm proper cell morphology, and adherent cells were counted using an inverted microscope.
- DU-145, PC-3, and LNCaP cells were propagated in 150 cm 2 flasks, containing RPMI- 1640 or Dulbecco's modified Eagle media supplemented with 10% fetal bovine serum (FBS). Cells were removed from stock flasks using trypsin, centrifuged, resuspended in fresh media, and plated at a density of approximately 2,000 cells/well in 96-well culture plates. Final drug concentrations ranged from 0.05 to either 10 or 50 ⁇ M. Control experiments with no drug added (negative control) and 5-fluorouracil added (positive control) were performed in parallel. Media was removed and replaced at 48 hours to minimize the effects of drug degradation during the course of the experiment.
- FBS fetal bovine serum
- N-palmitoyl-L-serine (15:0) WA WA WA WA
- the first and the second sets involve the amalgamation of the endogenous inhibitors SPH and SPP with the synthetic inhibitor N-palmitoyl L-serine phosphoric acid, whereas the third series involves the bisphosphates.
- Compounds 56, 57, 66 and 92 were inhibitors of LPA-induced chloride cu ⁇ ents in the Xenopus oocyte assay.
- RH7777 cells were chosen as a model system since they have been reported to be non- responsive to LPA in a variety of cellular assays and were found to be devoid of mRNA for any of the known Edg receptors (Fukushima et al., 1998). Stable cells lines transfected with the EDG receptors, as well as control cell lines transfected with empty vector, were established in RH7777 cells.
- the resulting clones were screened by monitoring intracellular Ca 2+ transients, and by RT-PCR. This screening process led to the identification of at least three positive cell lines expressing Edg-2 and -7, while no positive cell lines expressing Edg-4 could be identified. Vector transfected cells were also found to be non-responsive to LPA. Although stable clones expressing Edg-4 were not isolated, the transient expression of Edg-4 resulted in the LPA-mediated activation of intracellular Ca 2+ transients, demonstrating that the construct was functionally active in these cells.
- the stable Edg-4 cell line used in these experiments was isolated and characterized by Im et al., who kindly provided us with the same clone (Im et al., 2000).
- the cell lines were further characterized in an effort to identify a suitable assay for screening potential antagonists.
- LPA-elicited activation of ERK 1/2 was seen in Edg-2 and transient Edg-4 expressing cells, whereas ERK 1/2 was not activated in Edg-7 expressing cells.
- Dose response curves revealed EC 50 values of 378 ⁇ 53,
- Phosphatidic acid (PA) and diacylglycerol pyrophosphate (DGPP) are naturally occurring lipids which share some key chemical properties with the LPA pharmacophore, having an ionic phosphate group(s) and fatty acid chains. Neither is an agonist of the Edg receptors (see below). With this similarity in mind, short-chain DGPP were prepared and tested as an inhibitor of Edg-2, -4, or -7. Figures 29A-D show the effect of a 10-fold excess of DGPP (8:0) on the Ca responses elicited by LPA in the stable cell lines.
- Inhibition curves were determined in cells expressing Edg-2 and -7, using increasing concentrations of DGPP 8:0, while the concentration of LPA was kept constant at the EC 50 relative to the receptor studied.
- IC 50 values of 285 ⁇ 28 nM for Edg-7 ( Figure 30A) and 11.0 ⁇ 0.68 ⁇ M for Edg-2 ( Figure 31 A) were determined from the curves.
- the dose response curves for both Edg-7 ( Figure 30B) and Edg-2 ( Figure 3 IB) were shifted to the right, indicating a competitive mechanism of inhibition.
- neither PA analog enhanced the Ca 2+ response in cells with transient expression of Edg-4.
- DGPP 8:0 The effect of DGPP 8:0 on cells that endogenously express LPA receptors was also examined.
- DGPP 8:0 was found to inhibit the Ca 2+ -mediated, inward CI " cu ⁇ ents elicited by LPA in Xenopus oocytes with an IC 50 of 96 ⁇ 21 nM ( Figure 33A).
- Figure 33B the dose response curve for LPA 18:1 was shifted to the right, indicating a competitive mechanism of action as found in Edg-2 and -7 clones.
- DGPP 8:0 the expression of neurotransmitter receptors was induced by the injection of polyA+ mRNA from rat brain. This resulted in the expression of the G- protein coupled receptors for serotonin and acetycholine, which are not expressed in non-injected oocytes.
- These neurotransmitters activate the same inositol trisphophate-
- DGPP 8:0 did not inhibit either serotonin- or carbachol-elicited responses, demonstrating the specificity of DGPP 8:0 for the LPA receptors.
- PA 8:0 when used at similar concentrations was also effective at inhibiting the LPA-elicited responses in the oocytes.
- DGPP 8:0 The effect of DGPP 8:0 on LPA-elicited responses was also examined in mammalian systems that endogenously express LPA receptors.
- NIH3T3 cells were screened by RT-PCR for the presence of mRNA for the Edg and PSP24 receptors.
- Figure 34A shows that in NTH3T3 cells mRNA transcripts for Edg-2, -5, and PSP24 were detected.
- NTH3T3 cells were exposed to 100 nM LPA or SIP in the presence of 10 ⁇ M DGPP 8:0.
- DGPP 8:0 significantly inhibited the LPA-elicited Ca 2+ responses, whereas the S IP-elicited response was not effected.
- LPA has been shown to be generated from and play a role in ovarian cancer (Xu et al., 1995a). Therefore, DGPP 8:0 was also tested on HEY ovarian cancer cells to determine if it had an effect on a therapeutically relevant target.
- Figure 34D shows that DGPP 8:0 inhibited the LPA-elicited Ca 2+ response to 12% of control, whereas DGPP 18:1 had no effect. Likewise, PA 8:0 inhibited the Ca 2+ response to 6% of control, whereas PA 18:1 had no effect.
- HEY express mRNA transcripts for Edg-1, -2, -5, -7 receptors ( Figure 34C). Example 15 - Inhibition of NIH3T3 Cell Proliferation
- DGPP 8:0 The hallmark effect of a growth factor is its ability to elicit cell proliferation. Since LPA has been shown to stimulate the proliferation of a variety of different cell types (Goetzl et al., 2000), the ability of DGPP 8:0 to inhibit cell proliferation was examined in NIH3T3 cells. Figure 35 shows that DGPP 8:0 significantly inhibited the LPA-induced proliferation of NIH3T3 cells, reducing cell number to control levels, whereas it had no effect on the solvent-treated control cells. To define the structure-activity relationship for the inhibitory effect of DGPP 8:0, the short- and long-chain species of DGPP, PA, and DAG were included in the assay.
- RH7777 cells were used for heterologous expression of Edg-2, -4, and - 7 receptors to screen potential antagonists. Based on our previous computational modeling of the Edg receptors (Parrill et al. 2000) and the available structure-activity data (Jalink et al., 1995), the above experimental results demonstrate that the short- chain phosphatidate DGPP 8:0 is a selective, competitive antagonist of Edg-7, with an IC 50 value of 285 ⁇ 28 nM. The same molecule was found to be a poor inhibitor of Edg-2, with an IC 50 value of 11.0 ⁇ 0.68 ⁇ M, whereas it did not inhibit Edg-4. DGPP 8:0 inhibited the endogenous LPA response in Xenopus oocytes with an IC 50 value of
- Edg-7 also shows a preference for long-chain, unsaturated fatty acids over their saturated counte ⁇ arts.
- the presence of an ether linkage or vinyl-ether side chain also decreased the EC 50 by two orders of magnitude (Bandoh et al., 2000).
- there is an optimal hydrocarbon chain-length of 18 carbons whereas 20 carbon analogs were weaker agonists.
- DGPP and PA analogs confirmed this notion, as these compounds did not possess agonist properties in the Edg receptor expressing cell lines at concentrations up to 10 ⁇ M.
- DGPP 8:0 and PA 8:0 were found to be effective inhibitors of LPA-elicited CI " cu ⁇ ents in Xenopus oocytes.
- DGPP 8:0 was injected into oocytes followed by an extracellular application of LPA.
- DGPP 8:0 was only effective at inhibiting the LPA-elicited CI " currents when applied extracellularly, demonstrating that it exerts its antagonist effect on the cell surface.
- the specificity of DGPP 8:0 for LPA receptors was demonstrated in oocytes and NIH3T3 cells. In these cells, DGPP 8:0 was only effective at inhibiting the LPA-elicited Ca 2+ responses and not the responses elicited by SIP, acetycholine, or serotonin.
- RT-PCR analysis revealed that only Edg-2, and not Edg-4, or -7 is expressed in NTH3T3 cells.
- DGPP 8:0 In NIH3T3 cells, DGPP 8:0, at a high 100-fold excess, only inhibited the Ca 2+ responses by 40%. This degree of inhibition parallels that seen in the stable cell line expressing Edg-2, where it was also a weak inhibitor.
- short-chain DGPP and PA were evaluated on HEY ovarian cancer cells, at a 10-fold excess over LPA, both were effective inhibitors, whereas neither long-chain molecule had any effect.
- RT-PCR revealed that the predominant mRNA was for Edg-7 in HEY cells, whereas only a trace of Edg-2 mRNA was detected. This degree of inhibition parallels that seen in the stable cell line expressing Edg-7, where both DGPP 8:0 and PA 8:0 were effective inhibitors.
- DGPP 8:0 provides an important new tool for the field in studying, not only the Edg receptors but also other PLGF receptors.
- the concept of an ionic anchor and hydrophobic switch of the PLGF pharmacophore derived from computational modeling of the Edg family should assist the design and synthesis of new inhibitors.
- Xenopus oocytes which endogenously express PSP24 PLGFR were used to screen compounds 106-110 for their LPA inhibitory activity. Oocytes were obtained from xylazine-anesthetized adult Xenopus laevis frogs (Carolina Scientific, Burlington, NC) under aseptic conditions and prepared for experiment.
- Stage V-NI oocytes were denuded of the the follicular cell layer with type A collagenase treatment (Boehringer, IN) at 1.4 mg/ml in a Ca 2+ -free ovarian Ringers-2 solution ((OR-2) 82.5 mM NaCl, 2 mM KC1, 1 mM MgCl 2 , 5mM HEPES, pH 7.5, with NaOH). Oocytes were kept in Barth's solution in an incubator between 17-20 °C and were used for 2-7 days after isolation.
- type A collagenase treatment Boehringer, IN
- OR-2 solution ((OR-2) 82.5 mM NaCl, 2 mM KC1, 1 mM MgCl 2 , 5mM HEPES, pH 7.5, with NaOH).
- Oocytes were kept in Barth's solution in an incubator between 17-20 °C and were used for 2-7 days after isolation.
- Electrophysiological recordings were carried out using a standard two- electrode voltage-clamp amplifier holding the membrane potential at -60 mV (GeneClamp 500, Axon Instruments, CA). Test compounds were dissolved in MeOH, complexed with fatty acid free BSA, and diluted with frog Na + -Ringers solution (120 nM NaCl, 2 mM KC1, 1.8 mM CaCl 2 , 5 mM HEPES; pH 7.0), which were applied through superfusion to the oocyte at a flow rate of 5 ml/min.
- Membrane currents were recorded with a NIC-310 digital oscilloscope (Nicolet, Madison, Wl). Applications were made at intervals of 15 mins (minimum) to allow for the appropriate washout and recovery from desensitization.
- Figure 36 shows the dose-dependent inhibition of LPA-induced chloride cu ⁇ ents by compounds 106-110.
- Compound 108 was the best inhibitor, having an IC 0 value of about 8.1 nM.
- Compounds with shorter or longer straight- chain alkyl groups showed decreasing efficacy in inhibiting LPA-induced chloride cu ⁇ ents, although compound 107 displayed a similar efficacy with an IC 50 value of about 10.2 nM.
- Figure 37 compares the EC 50 values for positive control solution (LPA alone), 25 nm, and a solution containing LPA and 100 nM of compound 108, 343 nM.
- LPA positive control solution
- compound 108 effectively inhibits LPA signalling of PSP24 receptors in Xenopus oocytes.
- compound 108 was also examined for its effectiveness as an antagonist of Edg-2, -4, and -7 receptors in RH7777 cells which heterologously express the individual receptors.
- Figure 38 shows the effect of compound 108 on the Ca 2+ responses in Edg-2, Edg-4, and Edg-7 expressing cells when exposed to a combination of LPA 18:1 and compound 108.
- concentration of LPA was chosen to be near the EC 50 .
- Compound 108 significantly inhibited the Ca 2+ responses to about 63% and 56% of control, respectively, in Edg-2 and Edg-7 expressing cell lines.
- compound 108 significantly increased the Ca responses to about 148% of control in Edg-4 expressing cell lines.
- straight-chain phosphates would be expected to selectively inhibit Edg-2 and Edg-7 activity in vivo and selectively enhance Edg-4 activity in vivo.
- Ventricular zone gene-1 encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex
- Jalink et al. "Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca - mobilizing stimulus for fibroblasts," J. Biochem. 265:12232-12239 (1990).
- Jalink and Moolenaar "Thrombin receptor activation causes rapid neural cell rounding and neurite retraction independent of classic second messengers,” J. Cell Biol. 118:411-419 (1992).
- Jalink et al. "Growth factor-like effects of lysophasphatidic acid, a novel lipid mediator," Biochimica. et. Biophysica. Acta. 1198:185-196 (1994a). Jalink et al., "Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho," J. Cell Biol. 126:801-810 (1994b).
- Verrier et al. "Wounding a fibroblast monolayer results in the rapid induction of the c- fos proto-oncogene," EMBOJ., 5:913-917 (1986). Wissing and Behrbohm, "Diacylglycerol pyrophosphate, a novel phospholipid compound," FEBSLett. 315: 95-99 (1993).
- Xu et al. "Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients," Clin. Cancer Res. 1:1223-1232 (1995a).
- Xu et al. "Effect of lysophospholipids on signaling in the human Jurkat T cell line," J.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002460319A CA2460319A1 (en) | 2001-09-17 | 2002-09-17 | Lpa receptor agonists and antagonists and methods of use |
JP2003528500A JP2005508319A (en) | 2001-09-17 | 2002-09-17 | LPA receptor agonists and antagonists and methods of use thereof |
EP02773455A EP1427424A4 (en) | 2001-09-17 | 2002-09-17 | Lpa receptor agonists and antagonists and methods of use |
AU2002336595A AU2002336595B2 (en) | 2001-09-17 | 2002-09-17 | LPA receptor agonists and antagonists and methods of use |
KR10-2004-7003918A KR20040035807A (en) | 2001-09-17 | 2002-09-17 | Lpa receptor agonists and antagonists and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/953,686 | 2001-09-17 | ||
US09/953,686 US20030130237A1 (en) | 2000-03-17 | 2001-09-17 | LPA receptor agonists and antagonists and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003024402A2 true WO2003024402A2 (en) | 2003-03-27 |
WO2003024402A3 WO2003024402A3 (en) | 2004-02-19 |
Family
ID=25494395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/029593 WO2003024402A2 (en) | 2001-09-17 | 2002-09-17 | Lpa receptor agonists and antagonists and methods of use |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030130237A1 (en) |
EP (1) | EP1427424A4 (en) |
JP (1) | JP2005508319A (en) |
KR (1) | KR20040035807A (en) |
AU (1) | AU2002336595B2 (en) |
CA (1) | CA2460319A1 (en) |
WO (1) | WO2003024402A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1678096A2 (en) * | 2003-10-09 | 2006-07-12 | The University Of Tennessee Research Corporation | Lpa receptor agonists and antagonists and methods of use |
WO2010016590A1 (en) | 2008-08-07 | 2010-02-11 | 国立大学法人 長崎大学 | Therapeutic or prophylactic agent for generalized pain syndrome |
US7939505B2 (en) | 2007-05-04 | 2011-05-10 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
US20040167185A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-3 receptor |
WO2004091496A2 (en) * | 2003-04-11 | 2004-10-28 | The University Of Tennessee Research Foundation | Lysophosphatidic acid analogs and inhibition of neointima formation |
EP1906972B1 (en) * | 2005-07-19 | 2013-09-11 | The University of Tennessee Research Foundation | LPA2 receptor agonist for treating diarrhea |
KR101584722B1 (en) * | 2011-09-19 | 2016-01-13 | 건국대학교 산학협력단 | Use of a ginseng gintonin as herbal medicine-derived ligand |
EP3089986B1 (en) * | 2013-12-30 | 2019-06-26 | Rxbio Inc. | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate |
KR102149957B1 (en) * | 2019-02-18 | 2020-08-31 | (주)진토닌케이유 | Composition for preventing hair loss or promoting hair growth containing gintonin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5480877A (en) * | 1993-11-02 | 1996-01-02 | Wisconsin Alumni Research Foundation | Use of lysophosphatidic acids to enhance fibronectin binding |
US5565439A (en) * | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
WO1998041213A1 (en) * | 1997-03-19 | 1998-09-24 | Lxr Biotechnology Inc. | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340568A (en) * | 1992-07-01 | 1994-08-23 | The Procter & Gamble Company | Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles |
US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
AU7071896A (en) * | 1995-09-14 | 1997-04-01 | Lxr Biotechnology Inc. | Compositions with anti-apoptotic activity, containing a mixture of phospholipids |
EP1069895A4 (en) * | 1998-03-18 | 2002-07-31 | Lxr Biotechnology Inc | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
EP1263752B1 (en) * | 2000-03-17 | 2007-12-05 | The University Of Tennessee Research Corporation | Lpa receptor agonists and antagonists and methods of use |
-
2001
- 2001-09-17 US US09/953,686 patent/US20030130237A1/en not_active Abandoned
-
2002
- 2002-09-17 WO PCT/US2002/029593 patent/WO2003024402A2/en active Application Filing
- 2002-09-17 CA CA002460319A patent/CA2460319A1/en not_active Abandoned
- 2002-09-17 JP JP2003528500A patent/JP2005508319A/en active Pending
- 2002-09-17 EP EP02773455A patent/EP1427424A4/en not_active Ceased
- 2002-09-17 AU AU2002336595A patent/AU2002336595B2/en not_active Ceased
- 2002-09-17 KR KR10-2004-7003918A patent/KR20040035807A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565439A (en) * | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
US5480877A (en) * | 1993-11-02 | 1996-01-02 | Wisconsin Alumni Research Foundation | Use of lysophosphatidic acids to enhance fibronectin binding |
WO1998041213A1 (en) * | 1997-03-19 | 1998-09-24 | Lxr Biotechnology Inc. | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP1427424A2 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1678096A2 (en) * | 2003-10-09 | 2006-07-12 | The University Of Tennessee Research Corporation | Lpa receptor agonists and antagonists and methods of use |
EP1678096A4 (en) * | 2003-10-09 | 2007-04-18 | Univ Tennessee Res Corp | Lpa receptor agonists and antagonists and methods of use |
EP2433946A1 (en) * | 2003-10-09 | 2012-03-28 | University of Tennessee Research Foundation | LPA receptor agonists and antagonists and methods of use |
EP2481743A1 (en) * | 2003-10-09 | 2012-08-01 | University Of Tennessee Research Foundation | LPA receptor agonists and antagonists and methods of use |
US7939505B2 (en) | 2007-05-04 | 2011-05-10 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US8501824B2 (en) | 2007-05-04 | 2013-08-06 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US8877729B2 (en) | 2007-05-04 | 2014-11-04 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US9339461B2 (en) | 2007-05-04 | 2016-05-17 | Marina Biotech, Inc. | Arginine-based lipids for delivery of therapeutics |
US9731016B2 (en) | 2007-05-04 | 2017-08-15 | Marina Biotech, Inc. | Tyrosine-based lipids for delivery of therapeutics |
WO2010016590A1 (en) | 2008-08-07 | 2010-02-11 | 国立大学法人 長崎大学 | Therapeutic or prophylactic agent for generalized pain syndrome |
Also Published As
Publication number | Publication date |
---|---|
CA2460319A1 (en) | 2003-03-27 |
AU2002336595B2 (en) | 2008-08-14 |
US20030130237A1 (en) | 2003-07-10 |
KR20040035807A (en) | 2004-04-29 |
WO2003024402A3 (en) | 2004-02-19 |
EP1427424A2 (en) | 2004-06-16 |
JP2005508319A (en) | 2005-03-31 |
EP1427424A4 (en) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6875757B2 (en) | LPA receptor agonists and antagonists and methods of use | |
US7947665B2 (en) | LPA receptor agonists and antagonists and methods of use | |
AU2002336595B2 (en) | LPA receptor agonists and antagonists and methods of use | |
AU2002336595A1 (en) | LPA receptor agonists and antagonists and methods of use | |
US6245754B1 (en) | Inhibitors of phosphatidyl myo-inositol cycle | |
AU2001249263B2 (en) | LPA receptor agonists and antagonists and methods of use | |
AU2001249263A1 (en) | LPA receptor agonists and antagonists and methods of use | |
AU2007202615A1 (en) | LPA receptor agonists and antagonists and methods of use | |
CA2821433C (en) | Lpa receptor agonists and antagonists and methods of use | |
SG190816A1 (en) | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient | |
Sardar | Design and synthesis of phospholipid growth factor receptor inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002773455 Country of ref document: EP Ref document number: 2460319 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002336595 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003528500 Country of ref document: JP Ref document number: 1020047003918 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002773455 Country of ref document: EP |